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The term ‘athlete’s heart’ refers to a clinical picture characterized by a slow heart rate and enlargement of the heart. A multi-modality imaging
approach to the athlete’s heart aims to differentiate physiological changes due to intensive training in the athlete’s heart from serious cardiac dis-
easeswith similar morphological features. Imaging assessment of the athlete’s heart should begin with a thorough echocardiographic examination.
Left ventricular (LV) wall thickness by echocardiography can contribute to the distinction between athlete’s LV hypertrophy and hypertrophic
cardiomyopathy (HCM). LV end-diastolic diameter becomes larger (.55 mm) than the normal limits only in end-stage HCM patients when the
LV ejection fraction is ,50%. Patients with HCM also show early impairment of LV diastolic function, whereas athletes have normal diastolic
function. When echocardiography cannot provide a clear differential diagnosis, cardiac magnetic resonance (CMR) imaging should be performed.
With CMR, accurate morphological and functional assessment can be made. Tissue characterization by late gadolinium enhancement may show a
distinctive, non-ischaemic pattern in HCM and a variety of other myocardial conditions such as idiopathic dilated cardiomyopathy or myocarditis.
The work-up of athletes with suspected coronary artery disease should start with an exercise ECG. In athletes with inconclusive exercise ECG
results, exercise stress echocardiography should be considered. Nuclear cardiology techniques, coronary cardiac tomography (CCT) and/or
CMR may be performed in selected cases. Owing to radiationexposureand theyoung ageof most athletes, the use of CCT and nuclear cardiology
techniques should be restricted to athletes with unclear stress echocardiography or CMR.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords Athlete’s heart † Left ventricular hypertrophy † Hypertrophic cardiomyopathy † Idiopathic dilated cardiomyopathy †
Arrhythmogenic right ventricular cardiomyopathy † Echocardiography † Cardiac magnetic resonance † Coronary
cardiac CT † Nuclear cardiology
* Corresponding author. Tel: +39 081 7464749; Fax: +39 081 5466152, Email: mgalderi@unina.it
Published on behalf of the European Society of Cardiology. All rights reserved.& The Author 2015. For permissions please email: journals.permissions@oup.com.
European Heart Journal – Cardiovascular Imaging
doi:10.1093/ehjci/jeu323
 European Heart Journal - Cardiovascular Imaging Advance Access published February 13, 2015
by guest on February 15, 2015
D
ow
nloaded from
 
The approach to the athlete’s heart
Definition of the athlete’s heart and
physiological left ventricular hypertrophy
The term ‘athlete’s heart’ refers to a clinical picture characterized by
two distinct and specific cardiac effects induced by a sustained and
regular physical training programme, namely, slow heart rate (HR)
and enlargement of the heart.1,2 This is the result of haemodynamic
changes corresponding to HR reduction and stroke volume (SV)
increase along with the reduction in systemic vascular resistance.
Further haemodynamic changes include a slight elevation of cardiac
output (¼SV × HR) during exercise and a more pronounced
increase in blood pressure. From a physiological point of view, in
the long-run haemodynamic changes during exercise lead to an in-
crease in both left ventricular (LV) internal size (LV dilation) and LV
hypertrophy (LVH) which is generated in order to normalize LV
wall stress. Cardiac response to training is also influenced by additional
factors including hormonal stimuli and genetic susceptibility. LV dila-
tion and LVH may be pronounced enough to mimic a pathological
state, but LV systolic and diastolic function are normal or even supra-
normal, a feature which is the very nature of the athlete’s heart.
Of interest, in the athlete’s heart ejection fraction (EF), i.e. the per-
centage of blood in the left ventricle at-end-diastole, which is ejected
per beat, remains normal or can be even marginally reduced at rest.3
This perhaps surprising finding can be ascribed to different factors.
First of all, the formula used to calculate EF (100 × SV/LV end-
diastolic volume) is designed for individuals with normal sized LV
and can produce an intrinsic mathematical underestimation of LV
performance in the hearts of the athletes who generally have
increased LV end-diastolic volume. Furthermore, EF is an estimate
of the LV chamber function and not of myocardial contractility
itself: it can therefore underestimate LV ability to increase SV
during strenuous exercise. Finally and more importantly, EF of the
athletes increases markedly during effort when larger LV end-
diastolic volume allows to best utilize the Frank–Starling mechanism
(the higher preload, the more rapid diastolic filling, and the smaller LV
end-systolic volume) and increase SV compared with non-athletes.3,4
Accordingly, a truly comprehensive assessment of LV systolic func-
tion in athletes should be performed not only at rest but also
during exercise with standard echocardiography, advanced ultra-
sound techniques and other non-invasive cardiac imaging modalities.
However, despite these theoretical incentives to measure LV func-
tion and myocardial mechanics during exercise, the majority of the
studies have evaluated the athlete’s heart only at rest.
Differential impact of endurance
and strength training on the heart
(Morganroth hypothesis)
Endurance sports [dynamic (isotonic) exercise, e.g., running, walking,
cycling, swimming, rowing, and skiing) imply an aerobic training in
which the goal is prolongedathletic outputoveranextendeddistance
or for a long period of time. Strength training (isometric exercise, e.g.,
wrestling, weightlifting) is a type of physical exercise specializing in the
use of resistance to induce muscular contraction which builds the
strength, anaerobic endurance, and size of skeletal muscles.
Morganroth et al.5 hypothesized that morphological adaptations in
athletes correspond with the type of haemodynamic overload
imposed on the heart during exercise (Figure 1). Endurance training
would lead, as a consequence of volume overload and increased dia-
stolic wall stress, to eccentric LVH (LV mass increase with increased
LV cavity dimension). In contrast, strength training leads, as a conse-
quence of pressure overload and increased systolic wall stress, to
concentric LVH (increased wall thickness with no change in cavity
size). The ‘Morganroth hypothesis’ is not without its critics. Plenty
of evidence supported this hypothesis for endurance training, while
several studies failed to support the cardiac phenotype expected in
strength training.6 This may at least in part be explained by the fact
that some sports (soccer, rugby, hockey, etc.) include both endur-
ance and strength training programmes. Other factors include the
absence of standardized measurements, some degree of inaccuracy
of M-mode and 2D echocardiographic measurements and the con-
founding effect of the performance-enhancing substances abuse. In
addition, most of the studies challenging the ‘Morganroth hypothesis’
are cross-sectional by design. Figure 2 depicts two different types of
echocardiographically detected LVH in an endurance athlete and in
an athlete exerting mixed training, respectively. The ‘Morganroth hy-
pothesis’ needs therefore to be retested in longitudinal studies, asses-
sing well-defined exercise protocols and using standardized
measurements ideally with cardiac magnetic resonance (CMR) and/
or 3D echocardiography. It is noteworthy that a meta-analysis of 66
echocardiographic studies comparing 1451 athletes and 813 control
subjects showed significantly larger LV diameters and greater wall
thickness, with a relatively balanced LVH, in endurance as well as in
strength and combined (endurance + strength) training athletes.7
Data from the Italian pre-participation screening programmes
reported LV dilatation and LVH in large cohorts of young athletes
assessed by echocardiography. LV end-diastolic diameters varied
widely, but were found to be above normal in the majorityof athletes,
whereas LV wall thickness .12 mm was found only in a small per-
centage.1 LV EF is preserved (i.e. .50%) in the most of but not in
Figure 1: The ‘Morganroth hypothesis’. A ¼ no athlete, B ¼
Strength training athlete: concentric LV hypertrophy, C ¼
Endurance athlete: eccentric LV hypertrophy.
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all endurance athletes,8 and marginally low EF at rest does not equal
LV systolic dysfunction in athletes. LV diastolic function remains also
normal, independent of the training type.9 The volume load of endur-
ance training also influences the right ventricle, which is commonly
enlarged in endurance athletes.10
EACVI expert consensus key points
† The original Morganroth hypothesis differentiates eccentric LVH
seen in athletes performing endurance training from concentric
LVH in athletes undergoing strength training.
† The ‘Morganroth hypothesis’ for endurance training is well sup-
ported by evidence, while several studies failed to support the
cardiac phenotype expected in strength training.
Sudden cardiac death in athletes
The cardiovascular benefits of regular exercise are established11 and
most sports activities are presumed to be good for health. The effects
of competitive sports and vigorous exercise training and longevity
are, however, uncertain.12,13 Excessive training should, therefore,
not be regarded as a negligible risk. Although sudden cardiac death
(SCD) in athletes is rare, sport activity in adolescent and young ath-
letes is associated with an increased risk of SCD, which has a variable
incidence (0.5–2.3 per 100 000 person-years) and is more common
in males.14– 16 However, incidence and numbers might be underesti-
mated. The aetiology of SCD in athletes ,35 years is mostly inher-
ited and caused by structural heart disease, such as hypertrophic
cardiomyopathy (HCM) and arrhythmogenic right ventricular car-
diomyopathy (ARVC). In contrast, in athletes .35 years the vast
majority of SCD is a consequence of acquired disease, in particular
coronary artery disease (CAD).17 Table 1 shows an overview of
the most common aetiologies of SCD. More widespread use of
genetic analysis following autopsies now allows to reveal previously
undiscovered causes of SCD at ordinary autopsies.18,19
EACVI expert consensus key points:
† Intense sport activity in adolescent and young athletes is
associated with an increased risk of SCD, which has an incidence
ranging between 0.5 and 2.3 per 100 000 person-years and is
more common in males. However, incidence and numbers
might be underestimated.
† The aetiology of SCD in athletes,35 years is mostly inherited, it
being due to structural heart disease (mainly HCM and ARVC). In
contrast, the vast majority of SCD in athletes .35 years is a
consequence of acquired disease, in particular CAD.
Figure 2: Different kinds of LVH in two athletes with different
training patterns. LV mass index (indexation for both BSA and
height powered to 2.7) defines the presence of clear-cut LVH
(cut-off values in men:.115 g/m2 or.48 g/m2.7) whereas relative
wall thickness (2 × posterior wall thickness/LV internal end-dia-
stolic diameter) (eccentric ≤ 0.42, concentric. 0.42) (see Lang
RM et al.81). The upper panel depicts an eccentric type of LV hyper-
trophy (LV mass increase with increased LV cavity dimension) in an
endurance athlete (swimming). The cut-off point of LVH is achieved
by indexing LVM for BSA not for height;2.7 relative wall thickness
defines a concentric geometry. The lower panel depicts a LVH,
which is still eccentric (LV mass with increased LV cavity dimension)
but also mild increased LV wall thickness) in an athlete with ‘mixed’
training (combined endurance and strength training in rugby). The
cut-off point for LVH is achieved by indexing LV mass for both
BSA and height2.7; relative wall thickness shows an eccentric geom-
etry. IVSd, interventricular septal thickness in diastole; LViDd, LV in-
ternal end-diastolic diameter; LVPWD, LV posterior wall thickness
in diastole; EDV, End-diastolic volume, LVd Mass (ASE); LV mass in
diastole according to ASE, LVd mass index (for BSA); RWT, relative
wall thickness; LVMHt, LV mass index for height.2.7
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Most common aetiologies of sudden cardiac
death in athletes
Heritability Structurally
abnormal heart
Structurally normal
heart
Inherited Cardiomyopathies
HCM
ARVC
IDCM
Congenital coronary
anomalies
Bridged coronary
arteries
Aortic diseases
Channelopathies
Long QT syndrome
Brugada syndrome
Cathecol-aminergic
polimorphic
ventricular
tachycardia
Wolff–Parkinson–White
Acquired Myocardial ischaemia
Myocarditis
Cardiac sarcoidosis
Valvular heart disease
Commotio cordis
Drugs and stimulants
Electrolyte imbalance
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Cardiovascular effects of
performance-enhancing substances
The use of performance enhancing, illicit substances is an important
problem not only in competitive athletes.20 The list of drugs which
are banned is annually updated by the World Anti-Doping Agency
and includes anabolic agents and corticosteroids, peptide hormones,
growth factors and erythropoietin,b-2 agonists, hormone and meta-
bolic modulators, diuretics and masking agents, stimulants (amphet-
amine, cocaine), and cannabinoids. The majority of these drugs
interfere with training induced adrenergic hyperactivation and may
lead to unfavourable effects, such as arrhythmias, CAD, myocarditis,
pericarditis, heart failure, and SCD.
Drugs increasing lean muscle mass and enhancing performance
include testosterone and anabolic androgenic steroids. They stimu-
late cellular protein synthesis through adrenergic receptors and
promote the growth of all organs, including the heart, which have
receptors similar to those of androgens. Their cardiac effects can
include the development of myocardial fibrosis21 and blunt the
deconditioning effect on LVH usually observed in athletes, thus mis-
leading to the diagnosis of HCM. Accordingly, echocardiography
shows alterations of LV diastolic function,22 which are typically not
present in athletes who do not use steroids. Reduction of EF by
both standard echo23 and CMR24 as well as reduction of myocardial
strain by both Doppler-derived strain rate imaging25 and speckle
tracking echocardiography (STE)26 have been also observed in
steroids users.
Non-steroid agents producing anabolic effects includeb-2 agonist,
clenbuterol (used also to reduce body fat), human growth hormone
and insulin/insulin-like growth factors, human chorionic gonado-
tropin, erythropoietin, and selective androgen receptor modulators.
Although it is well known that the chronic use of these drugs can
induce LVH and LV diastolic dysfunction,27 their effects in competi-
tive athletes is poorly investigated by cardiac imaging. All stimulants
structurally related to amphetamine can cause catecholamine-
mediated cardiotoxicity (vasospasm, vasoconstriction, tachycardia,
arterial hypertension). As a consequence, the heart is compromised
resulting in LVH, myocardial fibrosis, and necrosis.27 The use of
cocaine is associated with acute and/or chronic cardiac disease, but
it may also induce regional wall motion abnormalities mimicking
premature CAD, aortic dissection, vasculitis, and stroke.28,29
Generally, screening of athletes by cardiac imaging can raise suspi-
cion about this kind of cardiotoxicity (Table 2) but cannot reliably
unmask the cardiotoxic effects of banned substances. This lack of re-
liability is also related to the fact that the use of these drugs is often
characterized by periods of abuse and intervals of abstinence in
order to maximize their performance-enhancing effects while
limiting the negative cardiac consequences. Furthermore, additional
drugs can be used to limit side effects and mask the doping
effects. However, the combination of LVH with diastolic dysfunction
and/or subclinical alteration of systolic function may raise suspicion
of a doping effect on the heart when other primary pathologies,
mainly HCM and arterial hypertension, have been excluded. In this
context, CMR can provide further information about the presence
of myocardial fibrosis as a main determinant of diastolic dysfunction
but cannot be considered conclusive.
EACVI expert consensus key points:
† Drugs increasing lean muscle mass and enhancing performance as
well as non-steroid agents producing anabolic effects may induce
myocardial fibrosis, which is consistent withLVHandalterationsof
LV diastolic function.
† The use of cocaine is associated with acute and chronic cardiac
disease but may also induce regional wall motion abnormalities
suggestive of premature CAD.
† Cardiac imaging cannot prove or rule out illicit substance abuse.
However, the combination of clear-cut LVH with diastolic dys-
function and/or subclinical alteration of systolic function may
raise the suspicion of illicit substance abuse when other primary
pathologies (HCM or arterial hypertension) are excluded. CMR
can provide additional information about the presence of myocar-
dial fibrosis but cannot be considered always conclusive.
The assessment of anatomy
and function
Differential diagnosis of athlete’s heart
from pathological remodelling of the
left ventricle
The role of echocardiography
Standard echocardiography has a pivotal role in differentiating
physiological and pathological LVH. In a series of 1309 athletes of dif-
ferent disciplines, 55% had increased LV end-diastolic diameter and
only 15% of the endurance athletes demonstrated values .60 mm,
always in the presence of a normal EF.2,6 However, in a study of
Abergel et al.3 the majority of elite cyclists had LV end-diastolic diam-
eter .60 mm. Cardiac size should be therefore considered in the
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Power of cardiac imaging for suspected
diagnosis performance-enhancing substances
involvement
Prohibited
substances
Cardiac effect Demonstration
by cardiac
imaging
Anabolic androgenic
substances
LVH, LV diastolic
dysfunction,
reduction of EF,
reduction of
longitudinal
strain
+++
Non-steroids anabolic
agents (B2 agonists,
peptide hormones,
growth factors,
recombinant human
erythropoietin)
LVH, LV diastolic
dysfunction
+
Stimulants
(amphetamines,
methamphetamine
and cocaine)
Acute and chronic
CAD, Aortic
dissection
++
+++, largely demonstrated; ++, well demonstrated; +, poorly demonstrated.
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context of exercise capacity given its robust association with VO2
max.30 A LV end-diastolic diameter .60 mm should therefore
raise the suspicion of an idiopathic dilated cardiomyopathy (IDCM)
when the LV dilation is out of proportion to the athlete’s condition-
ing. In 947 elite athletes, maximal end-diastolic septal wall thickness
was ≤12 mm in most. Only 1.7% had septal thickness .13 mm
(range ¼ 13–16 mm).31 Septal thickness was lower in women
(average ¼ 9 mm, upper limits ¼ 12 mm) compared with men of
the same age and body size.31 Moreover, LV remodelling in Afro-
caribbean athletes is characterized by similar cavity size but a dispro-
portionate wall thickening compared with Caucasians.32 In athletes
LVH involves equally the septal and the other LV walls. Conversely,
in HCM increased wall thickness (.15 mm) involves mainly the
basal septum, and in 20% of HCM cases is associated with additional
features, i.e. systolic anterior motion (SAM) of the mitral valve or
aortic valve mid-systolic closure.33 After cessation of exercise train-
ing (‘physical deconditioning’) for about 3 months a reduction of
maximum septal wall thickness (of about 15–33%) can be observed
in healthy athletes,34 whereas the reduction involving both septal
thickness (by 15%) and LV cavity dimension (by 7%) occurs after
1–13 years of training cessation.35 However, In 20% of the athletes
increased LV end-diastolic diameter was persistent even after an
average of 5 years of inactivity, despite normal LV function and no oc-
currenceof adversecardiac events.36 Conversely, reverse LV remod-
elling (both LV wall thickness and LV cavity dilation) does not occur in
pathological LVH. Likewise, LVH related to anabolic substance abuse
is typically not reversible even after 12 months of deconditioning.37
In athletes, LV mass increase is usually combined with normal EF
at rest,whereasSV isnormalorevenaugmented, as aresultof increased
preload (LV end-diastolic volume).1,5,37–39 Pulsed tissue Doppler
provides additional information for a comprehensive assessment of
functional properties of the athlete’s heart showing normal37 or supra-
normal40,41 myocardial systolic performance at rest. Accordingly, a
cut-off value ,9 cm/s of systolic peak velocity (s′, average of four
mitral annular sites) demonstrated 87% sensitivity and 97%specificity
in distinguishing pathological LVH (arterial hypertension or HCM)
from athlete’s LVH.42
Also LV diastolic function at rest can appear normal but is often
supranormal when compared with no trained individuals, in particu-
lar in endurance-trained athletes.37,43 Typically, the transmitral E/A
ratio is .2 in athletes (Figure 3). This feature helps to distinguish
physiological from pathological LVH, which is characterized by an
Figure3: Supranormal LV diastolic function in a competitive runner. In the upper panel, standard Doppler-derived transmitral patterns shows an
E/A ratio ¼ 2.97. In the lower panel, pulsed tissue Doppler-derived e′ velocity is very high at both septal (left) and lateral mitral annulus (right) and
E/e′ ratio ( ¼ 4.9) is consistent with a normal diastolic function.
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E/A ratio ,1 and a prolonged E velocity deceleration time. Pulsed
tissue Doppler-derived early-diastolic myocardial velocity (e′)
(Figure 3) and e′/a′ ratio of basal septal and basal lateral wall were
found to be increased in athletes.6,44 Of interest, e′ velocity of the
LV inferior wall was positively correlated with LV end-diastolic diam-
eter in endurance athletes since the predominant pre-load increase
of isotonic training induces a proportional improvement of myocar-
dial relaxation.9 Conversely, in patients with HCM, e′ velocity reduc-
tion occurred in both the hypertrophic septum and the normal
thickness of lateral wall.45 Regional diastolic dysfunction (e′/a′ ,1)
was detected in 25% of the myocardial segments of HCM patients
(including the non-hypertrophic walls) but was not present in any
segments of athletes.46 Also in hypertensive patients a reduction of
the septal e′/a′ ratio was observed, in particular in those with clear-
cut LVH.47 Increased E/e′ ratio at rest was found to correlate with
NYHA class and exercise capacity in HCM patients,48 whereas it
was found to be normal in athletes.39 However, there are few
descriptions of athletes with pathology and we cannot assume that
athletes with cardiomyopathies will exhibit the typical pathological
features seen in non-athletes with cardiomyopathies. Table 3 sum-
marizes LV key parameters, which should be measured by standard
echo Doppler examination in the athletes.
Advanced echocardiographic technologies have been used to
characterize the athlete’s heart and to distinguish physiological
and pathological LVH. Some studies analysed athlete’s heart by
STE.49–52 One of these studies found a slight reduction in global lon-
gitudinal strain (GLS) at rest that was compensated by an increase of
radial and circumferential strain in professional soccer players.48
Lower apical radial strain and lower LV twisting at rest were also
observed in cyclists than in sedentary controls.49 These reports
suggest LV adaptation of athletes at rest and also highlight the load
dependency of strain measurement. Athlete’s heart is in fact a very
interesting model of strain variation at loading conditions. In
another study a significant reduction of systolic and diastolic strain
and strain rate was found in hypertensives—but not in athletes—
with clear-cut LVH in comparison with normal sedentary controls.51
An e′/a′ ratio.1 was found in 100% of a large population of competi-
tive athletes, 90% of subjects had e′ ≥16 cm/s, s′ ≥10 cm/s, and GLS
≤216%.51 GLS was also found to be lower in 18 hypertensive
patients (217.5+ 2.8%) than in 22 elite rowers (222.2+ 2.7%)
and in 19 sedentary controls (221.1+ 2.0%) (P, 0.0001).53 In a
study comparing soccer players with HCM patients, radial strain—
but not longitudinal strain or pulsed tissue Doppler-derived
annular systolic velocities—differentiated the two groups.54 Very
recently, the combination of 2D STE and 3D volumetric assessment
allowed identifying different LV remodelling patterns in endurance-
trained (increased LV twisting), strength-trained, and mixed-trained
athletes.55 Albeit promising and useful to gain physiological informa-
tion on the athlete’s heart, the experience with STE is still preliminary
and does not yet support its routine use for the differential diagnosis
of athlete’s heart from pathologic LVH.
EACVI expert consensus key points:
† Standard echocardiography is the first-line exam fordifferentiating
athlete’s heart from pathologic LVH.
† In elite athletes the LV end-diastolic diameter is not frequently
increased .60 mm. A LV end-diastolic diameter .60 mm—
when combined with reduced EF and abnormal diastolic func-
tion—should raise suspicion of IDCM.
† In elite athletes LVH involves typically all myocardial segments and
the maximal septal thickness is usually ≤12 mm. Septal wall thick-
ness is lower in female athletes and more pronounced in African
than in Caucasian athletes.
† In HCM increased wall thickness (.15 mm) involves mainly the
basal septum and in 20% of HCM cases is associated with addition-
al features, such as SAM or aortic valve mid-systolic closure.
† After physical deconditioning of three months, a reduction of LV
wall thickness can be observed in athletes but not in HCM.
† In athletes LVH is combined with normal EF, normal, or even
increased SV and s′ velocity .9 cm/s, whereas s′ is ,9 cm/s in
HCM. EF is normal or high in early stages and possibly reduced
in advanced stages of HCM.
† LV diastolic function is often supranormal in athletes (E/A ratio
.2, increased e′ velocity, low E/e′ ratio). In the HCM E/A ratio
is ,1, E velocity deceleration time is prolonged, e′ velocity and
e′/a′ ratio are low. However, normal LV diastolic filling pattern
does not exclude pathological LVH.
The role of CMR
LV and RV volumes and mass as well as global and regional contractile
function can be accurately assessed with steady state free precession
(SSFP) cine CMR.56 –58 The excellent inter-study reproducibility of
cine CMR can be relevant when assessing not only the features
of the athlete’s heart but also individual changes, such as reduction
of LV wall thickness following training cessation. Quantification of
LV contraction and relaxation through measurements of myocardial
strain and strain-rate can be obtained by CMR tagging, but recently
introduced CMR feature of tissue tracking techniques allows deriv-
ation of such parameters also from routine SSFP cine images.59,60
Contrast enhanced CMR, using the late gadolinium enhancement
(LGE) imaging, enables differentiation of ischaemic from non-
ischaemic patterns of myocardial damage.61,62 Non-ischaemic
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Key echocardiographic measurements to be
measured in athletes
Left ventricle Right ventricle
LV mass index (g/m2)
LV end-diastolic volume (mL)
Septal wall thickness (mm)
LV EF (%)
LV SV (mL)
LV CO (L/min)
Transmitral E/A ratio
E velocity deceleration time (ms)
Annular s′ velocity (ms)
Annular e′ velocity (cm/s)
E/e′ ratio
e′/a′ ratio
RV free wall (mm)
RV basal diameter (mm)
RV base to apex diameter (mm)
TAPSE (mm)
IVC size (mm)
IVC respiratory reactivity (%)
A, transmitral atrial velocity; a′ , annular atrial velocity (pulsed tissue Doppler);
CO, cardiac output; E, transmitral early-diastolic velocity; e′ , annular early-diastolic
velocity (pulsed tissue Doppler); EF, ¼ ejection fraction; IVC, inferior vena cava;
LV, left ventricular. RV, right ventricular; s′ , annular systolic velocity (pulsed tissue
Doppler) TAPSE, tricuspid annular plane systolic excursion.
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patterns of myocardial damage include a subendocardial ring of
enhancement (myocardial amyloid), patchy enhancement (HCM),
or mid-myocardial and epicardial hyper-enhancement (myocarditis
or Anderson Fabry’s disease).63 A more recent and promising
CMR methodology, T1 mapping, provides the assessment of diffuse
myocardial fibrosis either using native T1 values or through quantifi-
cation of the extracellular volume from pre- and post-contrast T1
mapping, which cannot be visualized using LGE.64 This may further in-
crease the diagnostic accuracy to identify pathological LVH.
CineCMRwasusedtodifferentiateathlete’sheart frompathological
LVH using multiple geometric measures.65 Twenty-eight normal con-
trols, 25 elite athletes, 35 patients with HCM, 18 hypertensive
patients, and 24 patients with LVH due to aortic valve stenosis
were assessed. LV diastolic wall to volume ratio, which corresponds
substantially to echocardiographic derived relative wall thicknesses,
had the highest area under the curve (0.993) providing a sensitivity
of 80% and a specificity of 99% to distinguish athlete’ heart
(,0.15 mm × m2/mL) from all forms of pathologic LVH. No false-
positives and false-negatives were identified when differentiating
athlete’s hearts from pathological LVH using a multivariate logistic
regression model with multiple geometric measures. Single or com-
bined geometric measures using CMR were not able to differentiate
various other forms of pathological LVH such as HCM or that due to
arterial hypertension. The potential advantage of CMR over echo-
cardiography was also demonstrated.66 Compared to the reference
CMR, echocardiography missed LVH in 6% of cases with suspected
HCM and underestimated the maximal LV end-diastolic wall thick-
ness by 20%; echocardiography also failed to document LV end-
diastolic wall thickness. 30 mm in 10% of cases. In subjects with ab-
normal ECGs but normal or borderline echocardiogram, CMR was
able to identify patients with HCM and apical HCM (wall
thickness. 28 mm).67 LGE derived non-ischaemic pattern was
described in multiple studies of HCM.68–70 Of interest, a small
prevalence of LGE was demonstrated even in non-hypertrophied
myocardial segments.71,72 Figure 4 shows a CMR image in an endur-
ance athlete which facilitated a diagnosis of HCM, with LGE in the
hypertrophied septum indicating regional fibrosis. This suggests
that LGE increases the diagnostic accuracy over and above the geo-
metric measures that one can provide and determine using CMR
cines itself, but LGE absence cannot rule out HCM. On the other
hand, LGE can be seen in athletes without evidence of HCM.73 T1
mapping might be of potential use to distinguish athlete’s heart
from pathologic LVH but has never been systematically investigated
for this differential diagnosis.
Figure 4: Diagnosis of HCM in a 41-year old male endurance athlete by CMR. (A) The left ventricle is enlarged (LV end-diastolic diameter ¼ 58
mm), septal thickness is 15 mm. (B–D). LGE revealed myocardial fibrosis of anterior and inferior septum. Genetic analysis confirmed the diagnosis
of HCM.
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CMR can help to differentiate also athlete’s heart from IDCM not
only by providing high image quality and accurate measurements of
volumes and EF of both ventricles, but also by using LGE which
demonstrates mid-myocardial streaks in about one-third of sub-
jects.62,74,75 However, the absence of LGE cannot rule out IDCM.
Expert consensus key points:
† CMR is superior to echocardiography in differentiating athlete’s
heart from structural and functional changes which are related
with HCM (80% sensitivity and 90% specificity of cine CMR
derived LV diastolic wall to volume ratio , 0.15 mm × m2/mL
in athlete’s LVH).
† LGE may provide additional diagnostic information beyond geo-
metric measures obtained by simple cine CMR in order to differ-
entiate athlete’s heart from HCM.
† CMR can be helpful to distinguish athlete’s heart from IDCM not
only because of more accurate measurements of volumes and
EF compared with echocardiography, but also due to additional
information provided by LGE.
† The absence of LGE does not rule out HCM or IDCM.
Left atrial size and sport practice:
implications for normal ranges
Left atrial (LA) enlargement (Figure 5) is common in large cohorts of
athletes,76,77 because of LA pressure increase during exercise.
Whether increased LA size could be one potential determinant of
atrial fibrillation in athletes remains controversial.78 –80
By using standardized methods, echocardiographyallows identifica-
tion of LA enlargement.81 The 2D LA volume method (area-length
method or modified Simpson) is preferable to the linear LA antero-
posterior diameter. LA size should be indexed for the body surface
area (LA volume index ¼ LAVi).82,83 Current ASE/EAE recommenda-
tions on LV diastolic function indicate a cut-off point of≥34 mL/m2 of
2D LAVi for establishing LA enlargement.84 Demographic and an-
thropometric factors (e.g., ethnicity) are recognized determinants of
LAVi, whereas the role of ageing remains debated.85,86 Data from
the large sample size (n ¼ 734) of the NORRE study point out that
age and gender do not influence 2D LAVi in normal subjects.87
Prevalence of LA enlargement in competitive athletes were firstly
reported by Pelliccia et al. who found a mild increase of LA antero-
posterior diameter (≥40 mm) in 18% of athletes, a marked dilatation
(≥45 mm) in 2%, and a close association between LA diameter and
LV cavity dimension.76 LA enlargement appeared to be influenced
by the type of sport (greatest impact of sports which combines
endurance and strength training). Upper limits of LA diameters
(45 mm in women, 50 mm in men) were defined in athletes.
Figure 6 summarizes the data from two different studies that can be
used to justify different normal ranges for LA size in athletes than in
the normal population. The first study provided reference values
and relative impact of different sport activities and found LA enlarge-
ment (LAVi≥34 mL/m2) in 3.2% of the athletes.77 The key independ-
ent determinants of LAVi were training type and duration and LV
end-diastolic volume. The second study compared prospectively
LAVi determinants in healthy sedentary individuals and competitive
athletes over a wide age range87: LAVi above 34 mL/m2 was found
in some healthy controls but it was evident in 67% of athletes. Of
note, the ECG findings of isolated axis deviation or LA enlargement
in 579 of 2533 athletes (22.9%) does not predict major structural or
functional abnormalities at the echocardiographic evaluation.88 The
utilization of specific normal ranges (e.g. 95th percentile) of echocar-
diographic measured LAVi, ideally categorized by type of sport activ-
ity, could therefore help to avoid calling the findings of larger LA size
in athletes as abnormal.
STE-derivedLA strainhasbeen used toassess LA function, which is
enhanced in athletes89 and impaired in HCM patients.90 However, it
would be premature to currently recommend its clinical use for the
assessment of the athlete’s heart. Since echocardiography shows a
trend to underestimate LA volumes, CMR can be an attractive
alternative imaging modality.82,91 A very recent study demonstrated
that both LA and right atrial (RA) volumes, despite being larger in
athletes, did not differ from controls after normalization for total
heart volume. Of interest, LA volumes were marginally lower in
female athletes.92
Expert consensus key points:
† Upper limits of LA antero-posterior diameter (45 mm in women,
50 mm in men) have been defined in athletes.
† Although LAVi is preferred over LA antero-posterior diameter as
measureof LA size, currently normal rangeshavenot been defined
for LAVi in athletes. The normal range for sedentary healthy con-
trols (34 mL/m2) leads to frequent misclassification of dilated LA
cavities in athletes.
† There is a need to develop normal ranges for LAVi in athletes and
these should ideally be specific for gender and type of sport.
† Since echocardiography shows a trend to underestimate LA
volumes, CMR can be an attractive alternative imaging modality
and has confirmed less pronounced LA remodelling in female
than in male athletes.
Figure 5: Left atrial dilation in an endurance athlete (rower). The
current ASE/EAE recommendations on LV diastolic function indi-
cates a cut-off point ≥34 mL/m2 to define LA enlargement (see
Nagueh SF et al.83). Accordingly, LA volume index ¼ 38.055 mL/
m2 of this rower is consistentwithLAenlargement.However, thede-
velopment of athlete-specific normalcy criteria, ideally partitioned
according to gender and sport activity, could help avoid labelling
such left atrial dilation as pathological. LALs 4Ac, LA longitudinal
diameter in apical four-chamber view; LAAs A4c, LA area; LAESV
A-L A4C, LA end-systolic volume; LA Vol IND, LA volume index.
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RV chambers and function
Training activity has a well-known impact on the right heart cham-
bers, which react to increased blood volume with both RV and RA
dilation (Figure 7). Mild functional tricuspid regurgitation and dilation
of the inferior vena cava, but with preserved respiratory reactivity
(Figure 7), are also common. Once more than mild tricuspid regurgi-
tation is present, a structural heart disease should be sought for an
athlete. While the potential for concentric RV remodelling in athletes
is less clear, eccentric RV remodelling is common in athletes.93 The
upper limits of RV and RA dimensions were derived from a cohort
of 650 elite athletes using echocardiography. RV and RA dimensions
appeared to be greater in elite endurance-trained athletes than in
age- and sex-matched strength-trained athletes and sedentary con-
trols.94 Another echocardiographic study demonstrated a trend
towards thicker RV free walls and larger RV cavities in 127 male
elite endurance athletes.95 Also, the inferior vena cava appeared to
be dilated (average value ¼ 26 mm, upper limit ¼ 40 mm) in a
study involving 58 endurance athletes.96 Other reports confirmed
these observations using CMR and suggested a balanced RV and LV
enlargement with a similar balanced increase in RV and LV
mass.97,98 Controversial findings are available on the impact of
strength training on the right ventricle. RV dilation coupled with
enhanced systolic and diastolic function was observed in 40 endur-
ance athletes but not in 24 strength-trained athletes, these results
being possibly due to underpowered sample size of the second
group of athletes.99 In a recent systematic meta-analysis study of
training mode, RV dilatation was greater in the endurance group
than in controls but regression models demonstrated positive and
significant associations between body surface area and RV para-
meters.100 These results highlight the need of indexing RV para-
meters for the body surface area in athletes.
Standard echocardiography is the initial imaging modality of choice
for RV assessment in athletes.101 Normal values of RV wall thickness
are ,0.5 cm, as measured from the sub-costal or parasternal long-
axis views.81 Using M-mode or 2D imaging, RV-free wall thickness
should be measured at end-diastole at the level of the tricuspid
valve chords. The combination of multiple views permits to obtain
more information with an entire assessment of the areas of increased
wall thickness.81 RVenlargement should be identified by measuring at
least the RV basal diameter and RVbase to apexdiameter in the apical
Figure 6: Distribution of LA volume index in athletes. In the upper panel distribution of LAVi in a population of 615 athletes (D’Andrea et al.77).
In the lower panel distribution of LAVi in 158 athletes in comparison with 260 non-athletes (Nistri et al.86). Combined together these two studies
demonstrate that LAVi measurements should be considered in conjunction with the athletic state of individual subjects.
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four-chamber view.81 Typical RV features of the athlete’s heart (par-
ticularly in endurance athletes such as cycling, rowing, and canoeing)1
can resemble those found in ARVC, which can be suspected in ath-
letes with palpitations and/or arrhythmias. In ARVC the enlargement
of RV cavity involves both inflow and outflow and may be associated
with regional RV wall segmental morphological (thinning, bulging,
and aneurysms) and functional (regional wall motion) abnormal-
ities.102– 104 While in ARVC the left ventricle may also be affected
(i.e. regional wall motion abnormalities or LV dilatation), in athletes
RV cavity enlargement involves particularly RV inflow tract, is
almost always associated with LV enlargement (‘balanced enlarge-
ment’) but RV systolic function—which can be echocardiographically
detected by tricuspid annular plane systolic excursion, TAPSE is
typically normal or even supranormal. Table 3 summarizes RV key
parameters, which should be measured by the standard echo
Doppler examination in the athletes.
Among the advanced ultrasound technologies, 3D echocardiog-
raphy showed greater RV end-diastolic volumes and RV EF in 430
elite endurance-trained athletes compared with 250 sedentary con-
trols.105 By combining 3D echo and 2D STE of the right ventricle, it
appears that RV preload exerts its maximal influence on the lateral
longitudinal fibres (RV lateral longitudinal strain). Thismay contribute
to RV supranormal function in the athlete’s heart, as the findings had
been adjusted for potential confounders.106
In subjects with suboptimal echocardiographic images, CMR is the
reference standard for the assessment RV myocardial thickness and
chamber volumes, and offers high spatial and temporal reso-
lution.107– 110 CMR is also able to identify RV myocardial muscle
bands, such as the crista supraventricularis, which can be incorrect-
ly included in the measurements of maximal LV wall thickness on
echocardiographic assessment.110 If the diagnosis of AVRC is sus-
pected in athletes, CMR should always be requested. Although
the ARVC diagnostic criteria were not developed for the subgroup
of athletes, they highlight the importance of RV wall motion abnor-
malities, RV size, and function.111,112 CMR evidence for fibro-fatty
myocardial replacement in both RV and LV is not currently consid-
ered a diagnostic criterion for ARVC.111,112 It also needs to be con-
sidered that cardiac imaging, whether by echocardiography or CMR,
cannot confirm or exclude a diagnosis of ARVC on its own and clin-
ical features need to be considered. A possible effect of exercise in
accelerating the development of ARVC in athletes who are genetic-
ally predisposed should also be taken into account.113,114
EACVI expert consensus key points:
† Standard echocardiography is the first line cardiac imaging exam
for differentiating RV remodelling in athlete’s heart from patho-
logic right ventricles.
† Eccentric RV remodelling is common in athletes while the occur-
rence of concentric RV remodelling is unclear.
† A differential diagnosis of ARVC in athletes should be investigated
with echocardiography and CMR. Neither imaging modality may
confirm or exclude the diagnosis of ARVC, which remains a clinical
diagnosis. RV dilatation and reduction in RV systolic function in the
absence of LV remodelling should raise suspicion that this cannot
be solely due to exercise training.
The detection of myocardial
ischaemia and delineation of
coronary anatomy in athletes
Cardiovascular disease is reported as one of the main causes of
SCD in athletes, due to CAD in older or congenital coronary
artery anomalies in younger athletes. At present, there is a broad
range of screening recommendations for the diagnosis of myocar-
dial ischaemia in athletes with important variations between coun-
tries, type of sport and competition level.115 In 2007, the AHA
suggested that a medical supervised exercise ECG testing should
be performed only in competitive male athletes older than 40
years (or women older than 55 years) and at least two additional
cardiovascular risk factors or in persons with a markedly abnormal
single risk factor.116 In 2011, the sections of Exercise Physiology and
Sports Cardiology of the European Association of Cardiovascular
Prevention and Rehabilitation stated that maximal exercise testing
should be restricted to high-risk persons with at least moderate
Figure7: Rightventricularenlargementand inferiorvenacavadila-
tion in an endurance athlete. Upper panel: The apical four-chamber
view shows increase of both RV basal diameter (1¼ 33.34 mm)
and of RV base-to-apex length diameter 2¼ 81.11 mm). References
normal values (RV basal diameter¼ 20–28 mm, RV base-to-apex
length diameter ¼ 71–79 mm) from Lang et al.81). Lower panel:
M-mode recording inferior vena cava. 1 Maximal diameter¼ 34.04
mm, 2 minimal diameter ¼ 13.62 mm. In athletes, inferior vena cava
dilation is typically associated with extremely good respiratory
reactivity.
M. Galderisi et al.Page 10 of 21
by guest on February 15, 2015
D
ow
nloaded from
 
intensity activity.117 While much recent debate has focused on the
efficacy of screening with ECG, current evidence suggests that the
incremental cost-effectiveness ratio of cardiac imaging modalities is
too high (above country-specific willingness-to-pay thresholds) in
the context of a low prevalence of disease to justify their large
use as primary screening modalities in athletes.118
Echocardiography
Systematic and accurate exploration of proximal coronary arteries
may be useful in identifying athletes with anomalous coronary
origin. Coronary ostia can be visualized in 90–92% of athletes using
echocardiography (Figure 8) and identification of anomalous ostia is
highly specific.119 However, the sensitivity of echocardiography in
detecting congenital coronary anomalies has never been reported.
Stress echocardiography
Exercise stress echocardiography is a low cost, widely available, feas-
ible, and safe technique, better accepted than pharmacological stress
echocardiography by athletes. It gives information about cardiac
function, reserve, exercise capacity, and arrhythmias. CAD may be
diagnosed by exercise stress echocardiography with moderate
sensitivity and specificity (about 76 and 88%, respectively), compar-
ing favourably with other stress-testing methods.120,121 However, in
athletes with anomalous implantation of coronary artery, the exer-
cise stress echo can be normal (absence of inducible ischaemia),
but this does not change the risk of SCD in such patients. Exercise
stress echo is also of particular interest in atheletes with EF ,45–
50% at rest to test if there is contractile reserve (¼EF increase)
during exercise. A considerable EF increase suggests low EF at rest
to be related to low preload, and not to LV systolic dysfunction.
Using adenosine stress echocardiography in endurance athletes, a
supernormal coronary flow reserve (5.9+ 1.0 vs. 3.7+0.7 in con-
trols, P, 0.01) in the distal left anterior descending coronary
artery was observed. The hyperaemic flow velocities were higher,
whereas resting flow velocities were lower than in controls.122
Cardiac nuclear imaging
Very limited data exist on the use of myocardial perfusion imag-
ing (MPI) in asymptomatic athletes. Non-attenuation-corrected
99mTc-sestamibi SPECT imaging was used to evaluate 18 young
male elite athletes and myocardial perfusion defects were observed
in areas with LVH, reducing the specificity of SPECT in the athlete’s
setting.123 In another study, resting thallium-201 myocardial perfu-
sion defects were common in young male endurance athletes but
were not associated with echocardiographically detected LV wall
motion abnormalities.124 Using positron emission tomography
(PET) and measuring myocardial blood flow, oxygen consumption
and free fatty acid uptake with [15O]H2O, [
15O]O2, and [
18F]FTHA
during euglycaemic hyperinsulinaemia,125 myocardial oxygen con-
sumption, and blood flow per unit mass of the myocardium were
found to be reduced in endurance athletes compared with sedentary
subjects. This can be explained by reduced energy requirements due
to anatomical and physiological changes of the athlete’s heart as an
adaptation to endurance training. Myocardial fatty acid uptake was
not significantly changed during insulin stimulation. By assessing myo-
cardial metabolism using [18F]FDG PET,126 the rate of glucose uptake
per unit mass of the myocardium was similarly decreased in endur-
ance athletes and weightlifters with an increased LV mass compared
with sedentary men (Figure 9). Prolonged exercise training may also
alter the cardiac sympathetic function, which can be detected by
MIBG imaging. One study examined the ratio of heart/mediastinum
count (H/M) and the washout rates of 123I-MIBG in athletes and
normal controls. There was a significant decrease in 123I-MIBG myo-
cardial uptake in athletes, as well as an increased washout rate.127
Another study showed severely reduced myocardial MIBG uptake
of the inferior region in athletes with sinus bradycardia, suggesting se-
lective inferior myocardial wall sympathetic denervation, which may
be related to increased vagal tone and athlete’s bradycardia.128 The
magnitude to which this is a physiological or pathological change
and whether it could have prognostic implications needs to be clari-
fied. Taken together all these studies show that cardiac nuclear
imaging in the athlete’s setting is more suitable for research purposes
than for a clinical application and should not be recommended as a
first line test in competitive athletes.
Coronary cardiac tomography
Although coronary anomalies as well as myocardial bridging are fre-
quent findings in routine coronary cardiac tomography (CCT), the
exact prevalence is unknown, ranging for myocardial bridging from
15 to 85% at autopsy and 0.5 to 16% at coronary angiography.129
CCT offers the opportunity to evaluate coronary arteries non-
invasively (Figure 10) and, by using latest generations scanners, also
with a very low radiation dose.130 Moreover, subclinical CAD can
be detected also by calcium scanning.130 Owing to the high accuracy
of CCT—especially in terms of ruling out significant CAD—it could
provide valuable information also in the athletes setting. Considering
that especially endurance athletes have favourable lipid values and a
low-cardiovascular risk according to standard risk calculators, the
‘true’ cardiovascular risk might be underestimated. Moreover, the
association between premature CAD and endurance training, e.g.
marathon running, is discussed controversially. Mo¨hlenkamp
et al.131 reported higher calcium scores in athletes including 108
marathon runners compared with age- and risk-factor-matched
Figure8: Echocardiographic assessment of coronary origin in an
elite basketball player (red arrows), in a modified parasternal short-
axis view.This kindof imaging requiresanexperiencedoperatorand
good image quality to confidently identify the ostia and proximal
course of the coronary circulation. RCA, right coronary artery;
LMT, left main trunk; PV, pulmonary valve; AA, ascending aorta.
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controls. This observation is of major importance as coronary calci-
fication is an independent risk factor for all-cause mortality and car-
diovascular events in the general population. Whether these
observations can be generalized to athletes remains open to specu-
lation. However, at present CCT should not be recommended as a
first line imaging test in competitive athletes.132
Perfusion CMR imaging
Stressperfusion CMR imaging can help in the diagnosisof CAD in ath-
letes as in the general population. Stress CMR has become a routine
clinical test in many institutions, although it remains less available than
stress echocardiography and cardiac nuclear imaging.133 Current
ESC guidelines recommend stress CMR alongside other tests as a
gate keeper to invasive angiography in patients with suspected
CAD and intermediate pre-test probability.134 However, only very
few studies were performed using stress perfusion CMR in athletes
or in patients with HCM. In one of these, which compared 35 patients
with HCM and 14 healthy controls, vasodilator stress myocardial
perfusion was significantly reduced and correlated with the degree
of hypertrophy (as an expression of coronary microvascular dysfunc-
tion) in HCM patients.135 In cohorts of patients with overt HCM,
HCM mutation carriers, athlete’s heart with physiological LVH
and normal controls, myocardial perfusion reserve by CMR was
impaired only in overt HCM, but normal in athletes with LVH.136
Thus, if diagnostic uncertainty prevails in an athlete with LVH, perfu-
sion CMRcould provide additional information to facilitate the differ-
ential diagnosis. CMR may also play an important role in depicting
proximal coronary artery anomalies in athletes using coronary mag-
netic resonance angiography (MRA). Three-hundred-sixty healthy
men and women (207 athletes and 153 non-athletes) were assessed
with the standard CMR and an additional coronary MRA within a
maximum of 10 min scan time: among 335 individuals with technically
adequate CMR studies, four showed a malignant variant of the right
coronary artery. The authors concluded that a 10 min coronary
MRA is able to depict coronary origins and their proximal course.
Therefore, this technique may be used as a non-invasive tool to
exclude coronary artery anomalies in asymptomatic athletes under
35 years of age, as they have low risk of CAD.137
Figure 9: PET [18F]FDG uptake in athletes. Examples of PET images showing similarly decreased [18F]FDG uptake in endurance athletes and
weight lifters compared with sedentary men (modified with permission, Takala et al.126).
Figure 10: Image example of CCT. Non-invasive coronary angiography with not significant coronary artery stenosis. 1 LAD, 2 LCx, 3 RCA.
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Table 4 *Average and upper limits of the main echocardiographic LV parameters in elite athletes (*sample sizes≥400)
Athlete’s left heart morphologic and functional parameters Upper limit
Authors Journal Number of athletes Type of sport Parameter Average value
Pelliccia et al.1 Ann Intern Med 1999;130:23–31 1309 Endurance/strength LV end-diastolic diameter (adult male) (mm) 55 70
Whyte et al.167 Eur J Appl Physiol 2004;92:592–597 442 Endurance/strength LV end-diastolic diameter (adult female) (mm) 49 66
Pelliccia et al.168 JAMA 1996;276:211–215 600 Endurance/strength
Makan et al.170 Heart 2005;91:495–499 900 Endurance LV end-diastolic diameter (adolescent) (mm) 51 60
Spirito et al.31 Am J Cardiol 1994;74:802–806 947 Endurance/strength LV wall end-diastolic thickness (adult male) (mm) 10 16
Rawlins et al.169 Circulation 2010; 121:1078–1085 440 Endurance /strength LV wall end-diastolic thickness (adult female) (mm) 9.5 13
Sharma et al.6 J Am Coll Cardiol 2002;40:1431–1436 720 Endurance/strength LV wall end-diastolic thickness (adolescent) (mm) 9.5 12
Basavarajaiah et al.166 J Am Coll Cardiol 2008;51:2256–62 300 Endurance/strength LV wall end-diastolic thickness (black athlete) (mm) 11.5 16
Pelliccia et al.76 J Am Coll Cardiol 2005;46:690-696 1777 Endurance/strength LA diameter (male) (mm) 37 50
LA diameter (female) (mm) 32 45
D’Andrea et al.77 Am Heart J 2010;159:1155–1161 650 Endurance/strength LA volume index (male) (ml/m2) 28 36
LA volume index (female) (mL/m2) 26.5 33
D’Andrea et al.52 J Am Soc Echocardiogr 2010;23:1281–1288 650 Endurance /strength IVS Tissue Doppler s′ (cm/s) 13 18
IVS Tissue Doppler e′ (cm/s) 24 21
LV Tissue Doppler s′ (cm/s) 15 20
LV Tissue Doppler e′ (cm/s) 16 22
LV Tissue Doppler e′/a′ (cm/s) 1.45 1.7
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EACVI expert consensus key points:
† Albeit debated, ECG screening remains the first line test for the
diagnosis of heart disease in athletes.
† The incremental cost-effectiveness ratio of cardiac imaging modal-
ities is too high in the context of low prevalence to justify their
primary use for CAD diagnosis in asymptomatic athletes.
† Systematic andaccurateexplorationofproximal coronaryarteries
by echocardiography may be useful in identifying athletes with
anomalous coronary origin, but the sensitivity of echocardiog-
raphy in detecting congenital coronary anomalies has never
been reported.
† Pharmacological stress echocardiography is rarely performed in
athletes, whereas exercise stress echocardiography, a low cost,
widely available, feasible, and safe technique, is very well accepted
also by elite athletes.
† In symptomatic athletes in whom coronary anomalies or CAD
may be suspected, it is reasonable to consider CCT and/or
CMR, as well as attenuation-corrected SPECT MPI and PET MPI.
Intense exercise: good or
dangerous?
The positive effect of training exercise on LV contractile reserve is
recognized: preload is increased inendurance athletes,while afterload
is increased through higher systemic resistance during physical effort
in strength-trained athletes.37 However, intense endurance exercise
may not always be healthy. In some studies a transient reduction in
cardiac function of unknown clinical relevance has been observed in
endurance athletes. Immediately following exercise, acute increases
in troponin and B-type natriuretic peptide were reported, especially
when using high-sensitivity assays.138,139 Echocardiographic studies
showed that ‘cardiac fatigue’ could occur during prolonged exercise.
Marginaldecreaseofglobal andregional LVsystolic function (decrease
of EF), alterations of LV diastolic function, and appearance of regional
wall motion abnormalities were in fact documented in marathon
runners.140–143 Preload can be altered during exercise through dehy-
dration, redistribution of blood flow, and increased HR, whereas
afterload may be affected by changes in vascular resistance. Reduc-
tions of pulsed tissue Doppler-derived e′ velocity of both septal and
lateral annulus as well as of Tissue Doppler indices of RV function
were also reported after marathon completion.144,145 By using STE,
a decrease of longitudinal, circumferential and radial strains and also
a reductionanddelay of peak twisting was documented after ultralong
duration exercise in triathletes.146 Of note, while LV systolic dysfunc-
tion returned to normal within 48 h of the event, LV and RV diastolic
abnormalities persisted up to 1 month after the marathon participa-
tion. Exercise-induced symptoms and/or ischaemic-like ECG signs
were found to be often associated with a significant intraventricular
gradient (.50 mmHg during/after exercise) in the absence of wall
motion abnormalities in athletes.147 These findings do not automatic-
ally implypermanentmyocardial injuryandmay reflect temporaryepi-
sodes of micro-injury followed by complete recovery. It has been
speculated that this repair process may even strengthen the muscle
to better tolerate subsequent loads of equal or greater intensity. In
a study performed using PET imaging athletes had increased myocar-
dial perfusion and improved adenosine-induced myocardial blood
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flow reserve following a marathon run.148 However, LGE was ob-
served by CMR in 12% of marathon runners and its presence was
correlated with the number of marathons previously performed, sug-
gesting that intense sport activity could induce myocardial scarring.131
The right ventricle appears to be particularly vulnerable to the
effects of intense endurance exercise.146,149– 154 RV dilation follow-
ing an ultra-endurance triathlon without changes of LV dimensions
was observed by M-mode,143 2D echo148 – 150 and STE (reduction
of longitudinal strain 15% relative to baseline values).152 –154 The
upperphysiological limit of pulmonaryarterial systolic pressure in en-
durance athletes may reach 40 mmHg at rest, in line with the greater
increase in SV,155 and pulmonary arterial pressure increase during
exercise is more pronounced in athletes than in non-athletes.156
Obviously, pulmonary arterial pressure can increase during effort.
Repeated observations of RV dysfunction following prolonged
intense exercise would suggest that there is some point in time in
which the physiological demands of exercise can no longer be sus-
tained by RV metabolic reserves. It remains to be determined
whether recovery from repeated bouts of exercise-induced RV
dysfunction is complete in all athletes.
EACVI expert consensus key points:
† Transient ‘cardiac fatigue’ can occur during prolonged exercise.
† Marginal decreases of global and regional LV systolic function
(decrease of EF), alterations ofLV diastolic function, andappearance
of regional wall motion abnormalities have been documented in
endurance athletes.
† RV dilation following an ultra-endurance triathlon without
changes of LV dimensions has been observed and pulmonary
arterial pressure is more pronounced during intensive exercise
in athletes.
A proposal for multimodality
imaging for distinguishing athlete’s
heart from cardiac disease
Considerations regarding
pre-participation screening for the
prevention of SCD in athletes
Strategies for the prevention of SCD are endorsed by sport govern-
ing bodies but mandatory pre-participation screening remains
rare.157 The goal of pre-participation screening of competitive ath-
letes is the early identification of those with potentially fatal cardio-
vascular abnormalities, thus reducing the individual risk of SCD
during sport activity.115,158 Comprehensivepre-participation screen-
ing protocol in competitive athletes was established in Italy, in which
family history, physical examination, and 12-lead ECG at rest—very
effective for detection of electrical abnormalities and also HCM
Figure 11: Proposed EACVI algorithm for differential diagnosis between athlete’s heart and HCM or IDCM.
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and ARVC in athletes159 – 161—are combined. With this
protocol, near 90% reduction in the incidence rates of SCD from
3.6/100 000 per person-years to 0.4/100 000 per person-years
was demonstrated in a secular trend study.162 This is reflected in
the ESC guidelines, which recommend the inclusion of a ECG at
rest in pre-screening programmes.115 In the same guidelines, con-
ditions predisposing to SCD incorporate cardiac imaging (mainly
echocardiography) in athletes with suspected or ascertained con-
genital and acquired heart diseases.115 Conversely, the American
Heart Association does not consider cardiac imaging and not
support the routine use of the ECG in the athlete’s setting.116
Primary arguments against ECG use include the possibility of false-
positive results, high-incremental cost-effectiveness ratio, and psy-
chological implications for athletes and their families. Moreover,
the interpretation of the athlete’s ECG and recognition of
normal variants according to age, ethnicity, gender, sports modal-
ity, or competitive level is often difficult and requires specific ex-
pertise. Furthermore, a recent study from Israel reported no
change in SCD incidence rates in athletes following the implemen-
tation of screening programmes.163 The role of pre-participation
screening remains therefore controversial. To date, the current
evidence is not sufficient to justify the use of cardiac imaging as
primary screening modality in the guidelines on athletes, but
these concerns shall not be confused with the very useful applica-
tion of imaging for the assessment of athletes with symptoms,
abnormal ECG or positive family history.164
The potential role of multimodality
imaging
The multi-modality imaging approach of the athlete’s heart has
an important potential in order to differentiate it from serious
cardiac diseases, which may mimic physiologic changes due to in-
tensive training.165 Before cardiac imaging can be utilized in pre-
participation screening, specific reference values of the various
cardiac structural and functional parameters in athletes are needed.
Table 4 1,6,28,52,76,77,166– 172 and Table 5 93,155,173 show average
values and upper limits of the main echocardiographic LV and RV
parameters, respectively, established in studies with large sample
size in competitive (endurance and strength-trained) athletes.
Efforts should be made to collect normal values of some missing para-
meters and also presenting them according to race, gender, and
different sport disciplines. LV wall thickness is a key parameter
since it can contribute to the distinction between athlete’s LVH
and HCM. LV end-diastolic diameter is another hinge parameter.
Figure 12: Proposed EACVI algorithm for differential diagnosis between athlete’s heart and ARVC and diagnosis of CAD in athletes.
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Patients with HCM show also early impairment of LV diastolic func-
tion, whereas athletes have supranormal diastolic function.
Figures 11 summarizes multi-modality imaging algorithms which
can be applied to athletes when a suspicion of HCM and IDCM is
evident, whereas Figure 12 depicts cardiac imaging algorithms for
diagnosis of ARVC or CAD. Obviously, these algorithms cannot be
applied categorically. For instance, a reduction of LV wall thickness
may be observed in physiological LVH but also in athletes with
HCM, reflecting the complex interaction between genetic and envir-
onmental factors. Whenever, after echocardiography has been per-
formed, uncertainty remains concerning differential diagnosis of
athlete’s heart, measurements of key parameters by CMR and
tissue characterization by LGE CMR should be done in order to
establish a definite diagnosis. Since all cut-off values of HCM or
athlete’s heart were derived from echocardiographic studies, the
echo measurement could not be regarded as holding the same signifi-
cance by CMR. In accordance with 2013 ESC guidelines on the man-
agement of stable CAD,174 the work-up of athletes with suspected
CAD should start with exercise ECG testing as the first step.
When performing cardiac imaging tests, the presumably young age
of the athletes and therefore the lower pre-test probability of
CAD and the need to avoid exposure to radiation and increase the
inherent cancer risk should be taken into account. In athletes with
inconclusive results of maximal exercise ECG, it is reasonable to
consider physical stress echocardiography as the first cardiac
imaging choice and pharmacological stress echocardiography,
CMR, nuclear cardiology, and/or CCT in selected cases. If myocardial
ischaemia is detected by a first test, it is reasonable to propose inva-
sive coronary angiography without the performance of CCT, to avoid
cumulative tests and sometimes irradiation, if myocardial SPECT has
been performed first for example.
EACVI expert consensus key points:
† The goal of pre-participation screening of competitive athletes is
to identify those who have cardiovascular abnormalities, thus
reducing the risk of SCD during sport activity.
† ESC guidelines recommend pre-screening including ECG at rest,
but the American Heart Association does not recommend this.
† ESC guidelines propose echocardiography and, possibly, other
non-invasive cardiac imaging, in athletes with suspected or ascer-
tained congenital heart disease, heart valve disease, cardiomyop-
athies, and myocarditis.
† Normal ranges for all relevant cardiac parameters and for each
imaging technique are needed, by categorizing the majority of
parameters by gender and type of sport.
† CMR may help to differentiate athlete’s heart from other forms of
LVH and LV dilatation through demonstration of non-ischaemic
patterns of LGE, which would not be seen in exercise-related
remodelling.
† In athletes with suspected CAD, cardiac imaging provocative
tests should be performed when the results of exercise ECG
appear uncertain. Among provocative tests, physical exercise
echocardiography may be the first choice. The use of CCT and
nuclear cardiology techniques should be restricted to athletes
with unclear stress echocardiography.
Future perspective
Cardiac imaging is important in identifying cardiovascular disease in
athletes, but the final diagnosis has to be based on multiple factors
including medical history, sports history, training load, symptoms,
age, gender, ECG (resting and exercise), or genetic analysis. The con-
troversyof using echocardiography in the pre-participation screening
of competitive athletes is likely to remain as it is mainly around the
high-incremental cost-effectiveness ratio and the impact of false-
positive results on athletes and family. Although studies are still
limited, cardiac ultrasound using pocket size imaging devices might
offer a cheap but valid possibility of first-line imaging assessment175
also in athletes. Whenever needed, more advanced cardiac imaging
techniques, such as CCT, CMR, and nuclear imaging may add incre-
mental diagnostic and prognostic information. CMR LGE, CMR T1
mapping, low-dose CCT, and new PET tracers offer the greatest
potential.
Conflict of interest: none declared.
References
1. Pelliccia A, Culasso F, Di Paolo FM, Maron BJ. Physiologic left ventricular cavity dila-
tation in elite athletes. Ann Intern Med 1999;130:23–31.
2. Pelliccia A, Maron BJ, Spataro A, Proschan MA, Spirito P. The upper limit of physio-
logic cardiac hypertrophy in highly trained elite athletes. N Engl J Med 1991;32:
295–301.
3. Abergel E, Chatellier G, Hagege AA, Oblak A, Linhart A, Ducardonnet A et al. Serial
left ventricular adaptations in world-class professional cyclists: implications for
disease screening and follow-up. J Am Coll Cardiol 2004;44:144–9.
4. Wolfe LA, Cunningham DA, Davis GM, Rosenfeld H. Relationship between
maximal oxygen uptake and left ventricular function in exercise. J Appl Physiol
Respir Environ Exerc Physiol 1978;44:44–9.
5. Morganroth J, Maron BJ, Henry WL, Epstein SE. Comparative left ventricular
dimensions in trained athletes. Ann Intern Med 1975;82:521–4.
6. Sharma S, Maron BJ, Whyte G, Firoozi S, Elliott PM, McKenna WJ. Physiologic limits
of left ventricular hypertrophy in elite junior athletes: relevance to differential diag-
nosis of athlete’s heart and hypertrophic cardiomyopathy. J AmColl Cardiol2002;40:
1431–6.
7. Pluim BM, Zwiinderman AH, van der Laarse A, van der Wal EE. The athlete’s heart.
A meta-analysis of cardiac structure and function. Circulation 2000;101:336–44.
8. Gilbert CA, Nutter DO, Felner JM, Perkins JV, Heymsfield SB, Schlant RC. Echocar-
diographic study of cardiac dimensions and function in the endurance-trained
athlete. Am J Cardiol 1977;40:528–33.
9. Caso P, D’Andrea A, Galderisi M, Liccardo B, Severino S, De Simone L et al. Pulsed
Doppler tissue imaging in endurance athletes: relation between left ventricular
preload and myocardial regional diastolic function. Am J Cardiol 2000;85:1131–6.
10. Scharhag J, Schneider G, Urhausen A, Rochette V, Kramann B, Kindermann W. Ath-
lete’s heart: right and left ventricular mass and function in male endurance athletes
and untrained individuals determined by magnetic resonance imaging. J Am Coll
Cardiol 2002;40:1856–63.
11. Blair SN, Kohl HW III, Paffenbarger RS Jr, Clark DG, Cooper KH, Gibbons LW.
Physical fitness and all-cause mortality. A prospective study of healthy men and
women. JAMA 1989;262:2395–401.
12. Teramoto M, Bungum TJ. Mortality and longevity of elite athletes. J Sci Med Sport
2010;13:410–6.
13. Marijon E, Tafflet M, Antero-Jacquemin J, El Helou N, Berthelot G, Celermajer DS
et al.Mortality of French participants in the Tour de France (1947–2012).EurHeart
J 2013;34:3045–50.
14. Corrado D, Basso C, Rizzoli G, Schiavon M, Thiene G. Does sports activity enhance
the risk of sudden death in adolescents and young adults? J Am Coll Cardiol 2003;42:
1959–63.
15. Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young
competitive athletes: analysis of 1866 deaths in the United States, 1980–2006.
Circulation 2009;119:1085–92.
16. Maron BJ, Haas TS, Doerer JJ, Thompson PD, Hodges JS. Comparison of U.S. and
Italian experiences with sudden cardiac deaths in young competitive athletes and
implications for pre-participation screening strategies. Am J Cardiol 2009;104:
276–80.
17. Maron BJ. Sudden death in young athletes. N Engl J Med 2003;349:1064–75.
Multi-modality imaging and athlete’s heart Page 17 of 21
by guest on February 15, 2015
D
ow
nloaded from
 
18. Chandra N, Bastiaenen R, Papadakis M, Sharma S. Sudden cardiac death in young
athletes: practical challenges and diagnostic dilemmas. J Am Coll Cardiol 2013;61:
1027–40.
19. Terry GC, Kyle JM, Ellis JM Jr, Cantwell J, Courson R, Medlin R. Sudden cardiac
arrest in athletic medicine. J Athl Train 2001;36:205–9.
20. Deligiannis A, Bjo¨rnstad H, Carre F, Heidbu¨chel H, Kouidi E,
Panhuyzen-Goedkoop NM et al., ESC Study Group of Sports Cardiology. ESC
study group of sports cardiology position paper on adverse cardiovascular
effects of doping in athletes. Eur J Cardiovasc Prev Rehabil 2006;13:687–94.
21. Pluim BM, Katwinski PJ, Montgomery HE. Cardiaceffects of anabolic steroids.Heart
2004;90:473–5.
22. Nottin S, NguyenLD, Terbah M, Obert P. Cardiovascular effects of androgenic ana-
bolic steroids in male body builders determined by tissue Doppler imaging. Am J
Cardiol 2006;97:912–5.
23. Baggish AL, Weiner RB, Kanayama G, Hudson JI, Picard MH, Hutter AM Jr et al.
Long-term anabolic-androgenic steroid use is associated with left ventricular dys-
function. Circ Heart Fail 2010;3:472–6.
24. Luijkx T, Velthuis BK, Backx FJ, Buckens CF, Prakken NH, Rienks R et al. Anabolic
androgenic steroid use is associated with ventricular dysfunction on cardiac MRI
in strength trained athletes. Int J Cardiol 2013;167:664–8.
25. D’Andrea A, Caso P, Salerno G, Scarafile R, De Corato G, Mita C et al.Left ventricu-
lar early myocardial dysfunction after chronic misuse of anabolic androgenic ster-
oids: a Doppler myocardial and strain imaging analysis. Br J Sports Med 2007;41:
149–55.
26. Angell PJ, Chester N, Green DJ. Anabolic steroid use and longitudinal, radial and
circumferential cardiac motion. Med Sci Sports Exerc 2012;44:583–90.
27. Angell PJ, Chester N, Sculthorpe N, Whyte G, George K, Somauroo J. Performance
enhancing drug abuse and cardiovascular risk in athletes: implications for the clin-
ician. Br J Sports Med 2012;46(Suppl. I):I78–84.
28. Schwartz BG, Rezkalla S, Kloner RA. Cardiovascular effects of cocaine. Circulation
2010;122:2558–69.
29. Aquaro GD, Gabutti A, Meini M, Prontera C, Pasanisi E, Passino C et al. Silent myo-
cardial damage in cocaine addicts. Heart 2011;97:2056–62.
30. Steding K, Engblom H, Buhre T, Carlsson M, Mose´n H, Wohlfart B et al. Relation
between cardiac dimensions and peak oxygen uptake. J Cardiovasc Magnet Res
2010;12:8.
31. Spirito P, Pelliccia A, Proschan MA, Granata M, Spataro A, Bellone P et al. Morph-
ology of the ‘athlete’s heart’ assessed by echocardiography in 947 elites athletes
representing 27 sports. Am J Cardiol 1994;74:802–6.
32. Di Paolo FM, Schmied C, Zerguini YA, Junge A, Quattrini F, Culasso F et al.The ath-
lete’s heart in adolescent Africans: an electrocardiographic and echocardiographic
study. J Am Coll Cardiol 2012;59:1029–236.
33. Maron BJ. Structural features of the athlete heart as defined by echocardiography.
J Am Coll Cardiol 1986;7:190–203.
34. Maron BJ, Pelliccia A, Spataro A, Granata M. Reduction in left ventricular wall thick-
ness after deconditioning in highly trained Olympic athletes. Br Heart J 1993;69:
125–8.
35. Pelliccia A, Maron BJ, De Luca R, Di Paolo FM, Spataro A, Culasso F. Remodeling of
left ventricular hypertrophy in elite athletes after long-term deconditioning. Circu-
lation 2002;105:944–9.
36. Urhausen A, Albers T, Kindermann W. Are the cardiac effects of anabolic steroid
abuse in strength athletes reversible? Heart 2004;90:496–501.
37. Fagard R, Van Den Broeke C, Amery A. Left ventricular dynamics during exercise in
elite marathon runners. J Am Coll Cardiol 1989;14:112–8.
38. D’Andrea A, Limongelli G, Caso P, Sarubbi B, Della Pietra A, Brancaccio P et al. As-
sociation between left ventricular structure and cardiac performance during effort
in two morphological forms of athlete’s heart. Int J Cardiol 2002;86:177–84.
39. George KP, Warburton DE, Oxborough D, Scott JM, Esch BT, Williams K et al.
Upper limits of physiological cardiac adaptation in ultramarathon runners. J Am
Coll Cardiol 2011;57:754–5.
40. Florescu M, Stoicescu C, Magda S, Petcu I, Radu M, Palombo C et al. ‘Supranormal’
cardiac function in athletes related to better arterial and endothelial function. Echo-
cardiography 2010;27:659–67.
41. Zoncu S, Pelliccia A, Mercuro G. Assessment of regional systolic and diastolic wall
motion velocities in highly trained athletes by pulsed wave Doppler tissue imaging.
J Am Soc Echocardiogr 2002;15:900–5.
42. Vinereanu D, Florescu N, Schulthorpe N, Tweddel AC, Stephens MR, Fraser AG.
Differentiation between pathologic and physiologic left ventricular hypertrophy by
tissue Doppler assessment of long-axis function in patients with hypertrophic car-
diomyopathy or systemic hypertension and in athletes. Am J Cardiol 2001;88:53–8.
43. Fagard RH. Impact of different sports and training on cardiac structureand function.
Cardiology Clinics 1997;15:397–412.
44. D’Andrea A, Caso P, Severino S, Galderisi M, Sarubbi B, Limongelli G et al. Effects of
different training protocols on left ventricular myocardial function in competitive
athletes: a Doppler tissue imaging study. Ital Heart J 2002;3:34–5.
45. Severino S, Caso P, Galderisi M, De Simone L, Petrocelli A, de Divitiis O et al.Use of
pulsed Doppler Tissue Imaging to assess regional left ventricular diastolic dysfunc-
tion in hypertrophic cardiomyopathy. Am J Cardiol 1998;82:1394–8.
46. Cardim N, Gouveia Oliveira A, Longo S. Doppler tissue imaging: regional myocar-
dial function in hypertrophic cardiomyopathy and in athlete’s heart. J Am Soc Echo-
cadiogr 2003;16:223–32.
47. Galderisi M, Caso P, Severino S, Petrocelli A, De Simone L, Izzo A et al. Myocardial
diastolic impairment caused by left ventricular hypertrophy involves basal septum
more than other walls: analysis by pulsed Doppler tissue imaging. J Hypertens 1999;
17:685–93.
48. MatsumuraY, Elliott PM,Virdee MS,Virdee MS, Sorajja P,DoiYet al.Left ventricular
diastolic function assessed using Doppler tissue imaging in patients with hyper-
trophic cardiomyopathy: relation to symptoms and exercise capacity. Heart
2002;87:247–51.
49. Richand V, Lafitte S, Reant P, Serri K, Lafitte M, Brette S et al.An ultrasound speckle
tracking (two-dimensional strain) analysis of myocardial deformation in profession-
al soccer players compared with healthy subjects and hypertrophic cardiomyop-
athy. Am J Cardiol 2007;100:128–32.
50. Nottin S, Doucende G, Schuster-Beck I, Dauzat m, Obert P. Alteration in left ven-
tricular normal and shear strain evaluated by 2D-strain echocardiography in the
athlete’s heart. J Physiol 2008;586:4721–33.
51. Saghir M, Areces M, Makan M. Strain rate imaging differentiates hypertensive
cardiac hypertrophy from physiologic cardiac hypertrophy (athlete’s heart). J Am
Soc Echocardiogr 2007;20:151–7.
52. D’Andrea A, Cocchia R, Riegler L, Scarafile R, Salerno G, Gravino R et al. Left ven-
tricular myocardial velocities and deformation indexes in top-level athletes. J Am
Soc Echocardiogr 2010;23:1281–8.
53. Galderisi M, Lomoriello VS, Santoro A, Esposito R, Olibet M, Raia R et al. Differ-
ences of myocardial systolic deformation and correlates of diastolic function in
competitive rowersand young hypertensives: a speckle-tracking echocardiography
study. J Am Soc Echocardiogr 2010;23:1190–8.
54. Richand V, Lafitte S, Reant P, Serri K, Lafitte M, Brette S et al.An ultrasound speckle
tracking (two-dimensional strain) analysis of myocardial deformation in profession-
al soccer players compared with healthy subjects and hypertrophic cardiomyop-
athy. Am J Cardiol 2007;100:128–32.
55. Vitarelli A, Capotosto L, Placanica G, Caranci F, Pergolini M, Zardo F et al.Compre-
hensive assessment of biventricular function and aortic stiffness in athletes with dif-
ferent forms of training by three-dimensional echocardiography and strain imaging.
Eur Heart J Cardiovasc Imaging 2013;14:1010–20.
56. Pattynama PM, Lamb HJ, van der Velde EA, van der Wall EE, de Roos A. Left ven-
tricular measurements with cine and spin-echo MR imaging: a study of reproduci-
bility with variance component analysis. Radiology 1993;187:261–8.
57. Semelka RC, Tomei E, Wagner S, Mayo J, Caputo G, O’Sullivan M et al. Interstudy
reproducibilityof dimensional and functional measurements betweencine magnet-
ic resonance studies in the morphologically abnormal left ventricle. Am Heart J
1990;119:1367–73.
58. RehrRB, Malloy CR, Filipchuk NG, PeshockRM. Left ventricular volumesmeasured
by MR imaging. Radiology 1985;156:717–9.
59. Ceelen F, Hunter RJ, Boubertakh R, Sommer WH, Armbruster M, Schilling RJ et al.
Effect of atrial fibrillation ablation on myocardial function: insights from cardiac
magnetic resonance feature tracking analysis. Int J Cardiovasc Imaging 2013;29:
1807–17.
60. Augustine D, Lewandowski AJ, Lazdam M, Rai A, Francis J, Myerson S et al. Global
and regional left ventricular myocardial deformation measures by magnetic reson-
ance feature tracking in healthy volunteers: comparison with tagging and relevance
of gender. J Cardiovasc Magn Reson 2013;15:8.
61. Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O et al. Relationship of
MRI delayed contrast enhancement to irreversible injury, infarct age, and contract-
ile function. Circulation 1999;100:1992–2002.
62. Mahrholdt H, Wagner A, Judd RM, Sechtem U. Assessment of myocardial viability
by cardiovascular magnetic resonance imaging. Eur Heart J 2002;23:602–19.
63. Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. Delayed enhancement car-
diovascular magnetic resonance assessment of non-ischaemic cardiomyopathies.
Eur Heart J 2005;26:1461–74.
64. Moon JC, Messroghli DR, Kellman P, Piechnik SK, Robson MD, Ugander M et al.
Myocardial T1 mapping and extracellular volume quantification: a Society for Car-
diovascular Magnetic Resonance (SCMR) and CMR Working Group of the Euro-
pean Society of Cardiology consensus statement. J Cardiovasc Magn Reson 2013;
15:92.
65. Petersen SE, Selvanayagam JB, Francis JM, Myerson SG, Wiesmann F, Robson MD
et al. Differentiation of athlete’s heart from pathological forms of cardiac hyper-
trophy by means of geometric indices derived fromcardiovascular magnetic reson-
ance. J Cardiovasc Magn Reson 2005;7:551–8.
M. Galderisi et al.Page 18 of 21
by guest on February 15, 2015
D
ow
nloaded from
 
66. Rickers C, Wilke NM, Jerosch-Herold M, Casey SA, Panse P, Panse N et al.Utility of
cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyop-
athy. Circulation 2005;112:855–61.
67. Moon JC, Fisher NG, McKenna WJ, Pennell DJ. Detection of apical hypertrophic
cardiomyopathy by cardiovascular magnetic resonance in patients with non-
diagnostic echocardiography. Heart 2004;90:645–9.
68. Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM et al. Myocardial
scar visualized by cardiovascular magnetic resonance imaging predicts major
adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol
2010;56:875–87.
69. O’Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R et al. Prognostic
significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll
Cardiol 2010;56:867–74.
70. Petersen SE, Jerosch-Herold M, Hudsmith LE, Robson MD, Francis JM, Doll HA
et al. Evidence for microvascular dysfunction in hypertrophic cardiomyopathy:
new insights from multiparametric magnetic resonance imaging. Circulation 2007;
115:2418–25.
71. Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward
clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardio-
vascular magnetic resonance. J Am Coll Cardiol 2003;41:1561–7.
72. McCrohon JA, Moon JC, Prasad SK, McKenna WJ, Lorenz CH, Coats AJ et al. Dif-
ferentiation of heart failure related to dilated cardiomyopathy and coronary artery
disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation
2003;108:54–9.
73. Mangold S, Kramer U, Franzen E, Erz G, Bretschneider C, Seeger A et al. Detection
of cardiovascular disease in elite athletes using cardiac magnetic resonance imaging.
Rofo 2013;185:1167–74.
74. Maron BJ, Pelliccia A, Spirito P. Cardiac disease in young trained athletes. Insights
into methods for distinguishing athlete’s heart from structural heart disease, with
particular emphasis on hypertrophic cardiomyopathy. Circulation 1995;91:
1596–601.
75. Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, Khan M et al. Cardiovascular
magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll
Cardiol 2006;48:1977–85.
76. Pelliccia A, Maron BJ, Di Paolo FM, Biffi A, Quattrini FM, Pisicchio C et al.Prevalence
and clinical significance of left atrial remodeling in competitive athletes. J Am Coll
Cardiol 2005;46:690–6.
77. D’Andrea A, Riegler R, Cocchia R, Scarafile R, Salerno G, Gravino R et al. Left atrial
volume index in highly trained athletes. Am Heart J 2010;159:1155–61.
78. Molina L, Mont L, Marrugat J, Berruezo A, Brugada J, Bruguera J et al. Long-term
endurance sport practice increases the incidence of lone atrial fibrillation in men:
a follow-up study. Europace 2008;10:618–23.
79. Mont L, Elosua R, Brugada J. Endurance sport practice as a risk factor for atrial
fibrillation and atrial flutter. Europace 2009;11:11–7.
80. Mont L, Tamborero D, Elosua R, Molina I, Coll-Vinent B, Sitges M et al. GIRAFA
(Grup Integrat de Recerca en Fibril-lacio` Auricular) investigators. Physical activity,
height, and left atrial size are independent risk factors for lone atrial fibrillation in
middle-aged healthy individuals. Europace 2008;10:15–20.
81. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA et al.;
Chamber Quantification Writing Group; American Society of Echocardiography’s
Guidelines and Standards Committee; European Association of Echocardiography.
Recommendations for chamber quantification: a report fromthe American Society
of Echocardiography’s Guidelines and Standards Committee and the Chamber
Quantification Writing Group, developed in conjuction with the European
Association of Echocardiography, a branch of the European Society of Cardiology.
Eur J Echocardiogr 2006;7:79–108.
82. Abhayaratna WP, Seward JB, Appleton CP, Douglas PS, Oh JK, Tajik AJ et al. Left
atrial size: physiologic determinants and clinical applications. J Am Coll Cardiol
2006;47:2357–663.
83. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA et al.
Recommendations for the evaluation of left ventricular diastolic function by echo-
cardiography. Eur J Echocardiogr 2009;10:165–93.
84. Thomas L, Levett K, Boyd A, Leung DY, Schiller NB, Ross DL. Compensatory
changes in atrial volumes with normal aging: is atrial enlargement inevitable? J Am
Coll Cardiol 2002;40:1630–5.
85. Aurigemma GP, Gottdiener JS, Arnold AM, Chinali M, Hill JC, Kitzman D. Left atrial
volume and geometry in healthy aging. The Cardiovascular Health study. Circ Car-
diovasc Imaging 2009;2:282–9.
86. Nistri S, Galderisi M, Ballo P, Olivotto I, D’Andrea A, Pagliani L et al., on behalf of the
Working Groupof Echocardiographyof the Italian Society of Cardiology. Determi-
nants of echocardiographic left atrial size: implications for normalcy. Eur J Echocar-
diogr 2011;12:826–33.
87. Kou S, Caballero L, Dulgheru R, Voilliot D, De Sousa C, Kacharava G et al. Echocar-
diographic reference ranges from normal cardiac chamber size: results from
NORRE study. Eur Heart J Cardiovasc Imaging 2014;15:680–90.
88. Gati S, Sheikh N, Ghani S, Zaidi A, Wilson M, Raju H et al. Should axis deviation or
atrial enlargement be categorised as abnormal in young athletes? The athlete’s elec-
trocardiogram: time for re-appraisal of markers of pathology. Eur Heart J 2013;34:
3461–8.
89. D’Ascenzi F, Pelliccia A, Natali BM, Zaca` V, Cameli M, Alvino F et al. Morphological
and Functional adaptation of left and right atria induced by training in highly trained
female athletes. Circ Cardiovasc Imag 2014;7:222–9.
90. Gabrielli L, Enrı´quez A, Co´rdovaS, Ya´n˜ez F, Godoy I,Corbala´nR. Assessment of left
atrial function in hypertrophic cardiomyopathy and athlete’s heart: a left atrial myo-
cardial deformation study. Echocardiography 2012;29:943–9.
91. ScharfM, BremMH,WilhelmM,SchoepfUJ, UderM, LellMM. Atrial andventricular
functional and structural adaptations of the heart in elite triathletes assessed with
cardiac MR imaging. Radiology 2010;257:71–9.
92. Mose´n H, Steding-Ehrenborg K. Atrial remodelling is less pronounced in female
endurance-trained athletes compared with that in male athletes. Scand Cardiovasc
J 2014;48:20–6.
93. Knutsen KM, Stugaard M, Michelsen S, Otterstad JE. M-mode echocardiographic
findings in apparently healthy, nonathletic Norwegians aged 20–70 years. Influence
of age, sex and body surface area. J Intern Med 1989;225:111–5.
94. D’Andrea A, Riegler L, Golia E, Cocchia R, Scarafile R, Salerno G et al.Range of right
heart measurements in top-level athletes: the training impact. Int J Cardiol 2013;164:
48–57.
95. Hauser AM, Dressendorfer RH, Vos M, Hashimoto T, Gordon S, Timmis GC. Sym-
metric cardiac enlargement inhighly trained endurance athletes: a two-dimensional
echocardiographic study. Am Heart J 1985;109:1038–44.
96. Goldhammer E, Mesnick N, Abinader EG, Sagiv M. Dilated inferior vena cava: a
common echocardiographic finding in highly trained elite athletes. J AmSoc Echocar-
diogr 1999;12:988–93.
97. Scharhag J, Schneider G, Urhausen A, Rochette V, Kramann B, Kindermann W. Ath-
lete’s heart: right and left ventricular mass and function in male endurance athletes
and untrained individuals determined by magnetic resonance imaging. J Am Coll
Cardiol 2002;40:1856–63.
98. Scharf M, Brem MH, Wilhelm M, Schoepf UJ, Uder M, Lell MM. Cardiac magnetic
resonance assessment of left and right ventricular morphologic and functional
adaptations in professional soccer players. Am Heart J 2010;159:911–8.
99. Baggish AL, Wang F, Weiner RB, Elinoff JM, Tournoux F, Boland A et al. Training-
specific changes in cardiac structure and function: a prospective and longitudinal
assessment of competitive athletes. J Appl Physiol 2008;104:1121–8.
100. Utomi V, Oxborough D, Whyte GP, Somauroo J, Sharma S, ShaveRet al. Systematic
review and meta-analysis of training mode, imaging modality and body size influ-
ences on the morphology and function of the male athlete’s heart. Heart 2013;
99:1727–33.
101. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K et al.
Guidelines for the echocardiographic assessment of the right heart in adults: a
report from the American Society of Echocardiography endorsed by the European
Association of Echocardiography, a registered branch of the European Society of
Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr
2010;23:685–713.
102. Sen-ChowdhryS, Lowe MD, Sporton SC, McKenna WJ. Arrhythmogenic right ven-
tricular cardiomyopathy: clinical presentation, diagnosis, and management. Am J
Med 2004;117:685–95-.
103. Zaidi A, Ghani S, Sheikh N, Gati S, Bastiaenen R, Madden B et al.Clinical significance
of electrocardiographic right ventricular hypertrophy in athletes: comparison with
arrhythmogenic right ventricular cardiomyopathy and pulmonary hypertension.
Eur Heart J 2013;34:3649–56.
104. Sen-Chowdhry S, Prasad SK, McKenna WJ. Complementary role of echocardiog-
raphy and cardiac magnetic resonance in the non-invasive evaluation of suspected
arrhythmogenic right ventricular cardiomyopathy. J Interv Card Electrophysiol 2004;
11:15–7.
105. D’Andrea A, Riegler L, Morra S, Scarafile R, Salerno G, Cocchia R et al. Right ven-
tricular morphology and function in top-level athletes: a three-dimensional echo-
cardiographic study. J Am Soc Echocardiogr 2012;25:1268–76.
106. Esposito R, Galderisi M, Schiano-Lomoriello V, Santoro A, De Palma D, Ippolito R
et al. Nonsymmetric myocardial contribution to supranormal right ventricular
function in the athlete’s heart: combined assessment by Speckle Tracking and
real time three-dimensional echocardiography. Echocardiography 2013;31:
996–1004.
107. Nagueh SF, Bierig SM, Budoff MJ, Desai M, Dilsizian V, Eidem B et al. American
Society of Echocardiography; American Society of Nuclear Cardiology; Society
for Cardiovascular Magnetic Resonance; Society of Cardiovascular Computed
Tomography. American Society of Echocardiography clinical recommendations
for multimodality cardiovascular imaging of patients with hypertrophic cardiomy-
opathy: endorsed by the American Society of Nuclear Cardiology, Society for Car-
diovascular Magnetic Resonance, and Society of Cardiovascular Computed
Tomography. J Am Soc Echocardiogr 2011;24:473–98.
Multi-modality imaging and athlete’s heart Page 19 of 21
by guest on February 15, 2015
D
ow
nloaded from
 
108. Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE. 2011
ACCF/AHA guidelines for the diagnosis and treatment of hypertrophic cardiomy-
opathy: executive summary: a report of the American College of Cardiology Foun-
dation/American Heart Association Task Force on Practice Guidelines. Circulation
2011;124:2761–96.
109. Grothues F, Moon JC, Bellenger NG, Smith GS, Klein HU, Pennell DJ. Interstudy
reproducibility of right ventricular volumes, function, and mass with cardiovascular
magnetic resonance. Am Heart J 2004;147:218–23.
110. Maron MS. Clinical utility of cardiovascular magnetic resonance in hypertrophic
cardiomyopathy. J Cardiovasc Magn Reson 2012;1:14:13.
111. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA et al. Diagnosis
of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modifica-
tion of the task force criteria. Circulation 2010;121:1533–41.
112. Luijkx T, Velthuis BK, Prakken NH, Cox MG, Bots ML, Mali WP et al. Impact of
revised Task Force Criteria: distinguishing the athlete’s heart from ARVC/D
using cardiac magnetic resonance imaging. Eur J Prev Cardiol 2012;19:885–91.
113. Kirchhof P, Fabritz L, Zwiener M, Witt H, Scha¨fers M, Zellerhoff S et al. Age- and
training-dependent development of arrhythmogenic right ventricular cardiomyop-
athy in heterozygous plakoglobin-deficient mice. Circulation 2006;114:1799–806.
114. James CA, Bhonsale A, Tichnell C, Murray B, Russell SD, Tandri H et al. Exercise
increases age-related penetrance and arrhythmic risk in arrhythmogenic right ven-
tricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am
Coll Cardiol 2013;62:1290–7.
115. Corrado D, Pelliccia A, Bjørnstad HH, Vanhees L, Biffi A, Borjesson M et al. Study
Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and
ExercisePhysiologyand theWorking GroupofMyocardial andPericardialDiseases
of the European Society of Cardiology. Cardiovascular pre-participation screening
of young competitive athletes for prevention of sudden death: proposal for a
common European protocol. Consensus statement of the Study Group of Sport
Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physi-
ology and the Working Group of Myocardial and Pericardial Diseases of the Euro-
pean Society of Cardiology. Eur Heart J 2005;26:516–24.
116. Maron BJ, Thompson PD, Ackerman MJ, Balady G, Berger S, Cohen D et al., Ameri-
can Heart Association Council on Nutrition, Physical Activity, and Metabolism.
Recommendations and considerations related to pre-participation screening for
cardiovascular abnormalities in competitive athletes: 2007 update: a scientific
statement fromthe American Heart AssociationCouncil onNutrition, PhysicalAc-
tivity, and Metabolism: endorsed by the American College of Cardiology Founda-
tion. Circulation 2007;115:1643–455.
117. Borjesson M, Urhausen A, Kouidi E, Dugmore D, Sharma S, Halle M et al. Cardio-
vascular evaluation of middle-aged/ senior individuals engaged in leisure-time sport
activities: position stand from the sections of exercise physiology and sports cardi-
ology of the European Association of Cardiovascular Prevention and Rehabilita-
tion. Eur J Cardiovasc Prev Rehabil 2011;18:446–58.
118. La Gerche A, Baggish AL, Knuuti J, Prior DL, Sharma S, Heidbuchel H et al. Cardiac
imaging and stress testing asymptomatic athletes to identify those at risk of sudden
cardiac death. JACC Cardiovasc Imaging 2013;6:993–1007.
119. Zeppilli P, Dello Russo A, Santini C, Palmieri V, Natale L, Giordano A. In vivo detec-
tion of coronary artery anomalies in asymptomatic athletes by echocardiographic
screening. Chest 1998;114:89–93.
120. Garber AM, Solomon NA. Cost-effectiveness of alternative test strategies for the
diagnosis of coronary artery disease. Ann Intern Med 1999;130:719–28.
121. D’Andrea A, Severino S, Caso P, Liccardo B, Forni A, Fusco A et al. Prognostic value
of supine bicycle exercise stress echocardiography in patients with known or sus-
pected coronary artery disease. Eur J Echocardiogr 2005;6:271–9.
122. Hildick-Smith DJ, Johnson PJ, Wisbey CR, Winter EM, Shapiro LM. Coronary flow
reserve is supranormal in endurance athletes: an adenosine transthoracic echocar-
diographic study. Heart 2000;84:383–9.
123. Bartram P, Toft J, Hanel B, Ali S, Gustafsson F, Mortensen J et al. False-positive
defects in technetium-99 m sestamibi myocardial single-photon emission tomog-
raphy in healthy athletes with left ventricular hypertrophy. Eur J Nucl Med 1998;
25:1308–12.
124. Andersson LG, Henriksen E, Damm S, Jonason T, Niklasson U, Wessle´n L et al.
Thallium-201 myocardial imaging at rest in male orienteers and other endurance
athletes. Ups J Med Sci 2001;106:59–66.
125. Takala TO, Nuutila P, Katoh C, Luotolahti M, Bergman J, Ma¨ki M et al. Myocardial
blood flow, oxygen consumption, and fatty acid uptake in endurance athletes
during insulin stimulation. Am J Physiol 1999;277:E585–90.
126. Takala TO, Nuutila P, Knuuti J, Luotolahti M, Yki-Jarvinen H. Insulin action on heart
and skeletal muscle glucose uptake in weightlifters and endurance athletes. Am J
Physiol 1999;276:E706–11.
127. MatsuoS,NakamuraY,TakahashiM,MatsuiT,Kusukawa J,YoshidaSetal.Cardiac sym-
pathetic dysfunction in an athlete’s heart detected by 123I-metaiodobenzylguanidine
scintigraphy. Jpn Circ J 2001;65:371–4.
128. Estorch M, Serra-Grima R, Flotats A, Marı´ C, Berna` L, Catafau A et al. Myocardial
sympathetic innervation in the athlete’s sinus bradycardia: is there selective inferior
myocardial wall denervation? J Nucl Cardiol 2000;7:354–8.
129. Leschka S, Koepfli P, Husmann L, Plass A, Vachenauer R, Gaemperli O et al. Myo-
cardial bridging: depiction rate and morphology at CT coronary angiography—
comparison with conventional coronary angiography.Radiology 2008;246:754–62.
130. Schroeder S, Achenbach S, Bengel F, Burgstahler C, Cademartiri F, de Feyter P.
Cardiac computed tomography: indications, applications, limitations, and training
requirements: report of a Writing Group deployed by the Working Group
Nuclear Cardiology and Cardiac CT of the European Society of Cardiology and
the European Council of Nuclear Cardiology. Eur Heart J 2008;29:531–56.
131. Mo¨hlenkamp S, Lehmann N, Breuckmann F, Bro¨cker-Preuss M, Nassenstein K,
Halle M et al. Running the risk of coronary events: prevalence and prognostic rele-
vance of coronary atherosclerosis in marathon runners. Eur Heart J 2008;29:
903–1910.
132. Thiene G, Corrado D, Schiavon M, Basso C. Screening of competitive athletes to
prevent sudden death: implement programmes now. Heart 2013;99:304–6.
133. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A et al. ESC
guidelines on the management of stable coronary artery disease: the Task Force
on the management of stable coronary artery disease of the European Society of
Cardiology. Eur Heart J 2013;34:2949–3003.
134. Bruder O, Wagner A, Lombardi M, Schwitter J, van Rossum A, Pilz G et al.European
Cardiovascular Magnetic Resonance (EuroCMR) registry–multinational results
from 57 centers in 15 countries. J Cardiovasc Magn Reson 2013;15:9.
135. Petersen SE, Jerosch-Herold M, Hudsmith LE, Robson MD, Francis JM, Doll HA
et al. Evidence for microvascular dysfunction in hypertrophic cardiomyopathy:
new insights from multi-parametric magnetic resonance imaging. Circulation 2008;
115:2418–25.
136. Karamitsos TD, Dass S, Suttie J, Sever E, Birks J, Holloway CJ et al. Blunted myocar-
dial oxygenation response during vasodilator stress in patients with hypertrophic
cardiomyopathy. J Am Coll Cardiol 2013;61:1169–76.
137. Prakken NH, Cramer MJ, Olimulder MA, Agostoni P, Mali WP, Velthuis BK. Screen-
ing for proximal coronary artery anomalies with 3-dimensional MR coronary
angiography. Int J Cardiovasc Imaging 2010;26:701–10.
138. Shave R, Baggish A, George K, Wood M, Scharhag J, Whyte G et al.
Exercise-induced cardiac troponin elevation: evidence, mechanisms, and implica-
tions. J Am Coll Cardiol 2010;56:169–76.
139. Mousavi N, Czarnecki A, Kumar K, Fallah-Rad N, Lytwyn M, Han SY et al. Relation
of biomarkers and cardiac magnetic resonance imaging after marathon running.
Am J Cardiol 2009;103:1467–72.
140. Trivax JE, Franklin BA, Goldstein JA, Chinnaiyan KM, Gallagher MJ, de Jong AT et al.
Acute cardiac effects of marathon running. J Appl Physiol 2010;108:1148–53.
141. Shave R, George K, Whyte G, Hart E, Middleton N. Post exercise changes in left
ventricular function: the evidence so far. Med Sci Sports Exerc 2008;40:1393–9.
142. Neilan TG, Januzzi JL, Lee-Lewandrowski E, Ton-Nu TT, Yoerger DM, Jassal DS
et al. Myocardial injury and ventricular dysfunction related to training levels
among non elite participants in the Boston marathon. Circulation 2006;114:
2325–33.
143. Neilan TG, Yoerger DM, Douglas PS, Ton-Nu TT, Yoerger DM, Jassal DS et al. Per-
sistent and reversible cardiac dysfunction among amateur marathon runners. Eur
Heart J 2006;27:1079–84.
144. Cotrim C, Almeida AR, Miranda R, Almeida AG, Cotrim H, Picano E et al.
Stress-induced intraventricular gradients in symptomatic athletes during upright
exercise continuous wave Doppler echocardiography. Am J Cardiol 2010;106:
808–1812.
145. Nottin S, Doucende G, Schuster I, Tanguy S, Dauzat M, Obert P. Alteration in left
ventricular strains and torsional mechanics after ultralong duration exercise in
athletes. Circ Cardiovasc Imaging 2009;2:323–30.
146. Douglas PS, O’Toole ML, Hiller WD, Reichek N. Different effects of prolonged
exercise on the right and left ventricles. J Am Coll Cardiol 1990;15:64–9.
147. La Gerche A, Connelly KA, Mooney DJ, MacIsaac AI, Prior DL. Biochemical and
functional abnormalities of left and right ventricular function after ultra-endurance
exercise. Heart 2008;94:860–6.
148. Kallioski KK, Laaksonen MS, Luotolahti M, Laine H, Takala TO, Nuutila P et al.
Myocardial perfusion after marathon running. Scand J Med Sci Sports 2004;14:
208–14.
149. La Gerche A, Burns AT, Mooney DJ, Inder WJ, Taylor AJ, Bogaert J et al.
Exercise-induced right ventricular dysfunction and structural remodelling in
endurance athletes. Eur Heart J 2012;33:998–1006.
150. D’Andrea A, Caso P, Sarubbi B, Limongelli G, Liccardo B, Cice G et al. Right ven-
tricular myocardial adaptation to different training protocols in top-level athletes.
Echocardiography 2003;20:329–36.
151. La Gerche A, Heidbu¨chel H, Burns AT, Mooney DJ, Taylor AJ, Pfluger HB et al.
Disproportionate exercise load and remodeling of the athlete’s right ventricle.
Med Sci Sports Exerc 2011;43:974–81.
M. Galderisi et al.Page 20 of 21
by guest on February 15, 2015
D
ow
nloaded from
 
152. D’Andrea A, Caso P, Bossone E, Scarafile R, Riegler L, Di Salvo G et al. Right ven-
tricular myocardial involvement in either physiological or pathological left ventricu-
lar hypertrophy: an ultrasound speckle- tracking two-dimensional strain analysis.
Eur J Echocardiogr 2010;11:492–500.
153. Oxborough D, Shave R, Warburton D, Williams K, Oxborough A, Charlesworth S.
Dilatation and dysfunction of the right ventricle immediately after ultra-endurance
exercise: exploratory insights from conventional two-dimensional and speckle
tracking echocardiography. Circ Cardiovasc Imaging 2011;4:253–63.
154. La Gerche A, Burns AT, D’Hooge J, Macisaac AI, Heidbu¨chel H, Prior DL. Exercise
strain rate imaging demonstrates normal right ventricular contractile reserve and
clarifies ambiguous resting measures in endurance athletes. J Am Soc Echocardiogr
2012;25:53–262.
155. D’Andrea A, Naeije R, D’Alto M, Argiento P, Golia E, Cocchia R et al. Range in pul-
monary artery systolic pressure among highly trained athletes. Chest 2011;139:
788–94.
156. Bossone E, Rubenfire M, Bach DS, Ricciardi M, Armstrong WF. Range of
tricuspid regurgitation velocity at rest and during exercise in normal adult men:
implications for the diagnosis of pulmonary hypertension. J Am Coll Cardiol 1999;
33:1662–6.
157. Chandra N, Bastiaenen R, Papadakis M, Sharma S. Sudden cardiac death in young
athletes: practical challenges and diagnostic dilemma. J Am Coll Cardiol 2013;61:
1027–40.
158. Chandra N, Papadakis M, Sharma S. Pre-participation screening of young competi-
tive athletes for cardiovascular disorders. Phys Sports Med 2010;38:54–63.
159. Ljungqvist A, Jenoure PJ, Engebretsen L, Alonso JM, Bahr R, Clough AF et al. The
International Olympic Committee (IOC) consensus statement on periodic
atlhete evaluation of elite athletes, March 2009. Clin J Sport Med 2009;19:347–65.
160. Montgomery JV, Harris KM, Casey SA, Zenovich AG, Maron BJ. Relation of
electrocardiographic patterns to phenotypic expression and clinical outcome in
hypertrophic cardiomyopathy. Am J Cardiol 2005;96:270–5.
161. Marcus FI. Electrocardiographic features of inherited diseases that predispose to
the development of cardiac arrhythmias, long QT syndrome, arrhythmogenic
right ventricular cardiomyopathy/dysplasia, and Brugada syndrome. J Electrocardiol
2000;33:S1–S10.
162. Corrado D, Basso C, Pavei A, Michieli P, Schiavon M, Thiene G. Trends in sudden
cardiovascular death in young competitive athletes after implementation of a pre-
participation screening program. JAMA 2006;296:1593–601.
163. Steinvil A, Chundadze T, Zeltser D, Rogowki O, Halkin A, Galily Y et al. Mandatory
electrocardiographic screening of athletes to reduce their risk for sudden death.
J Am Coll Cardiol 2011;57:1291–6.
164. La Gerche A, Baggish AL, Knuuti J, Prior DL, Sharma S, Heidbuchel H et al. Cardiac
imaging and stress testing in asymptomatic athletes to identify those at risk of
sudden cardiac death. JACC Cardiovasc Imaging 2013;6:993–1007.
165. La Gerche A, Taylor AJ, Prior DL. Athlete’s Heart: the potential for multimodality
imaging to address the critical remaining questions. J Am Coll Cardiol Img 2009;2:
350–63.
166. Basavarajaiah S, Wilson M, Whyte G, Shah A, McKenna W, Sharma S. Prevalence of
hypertrophic cardiomyopathy in highly trained athletes: relevance to pre-
participation screening. J Am Coll Cardiol 2008;51:1033–9.
167. Whyte GP, George K, Sharma S, Firoozi S, Stephens N, Senior R et al. The upper
limit of physiological cardiac hypertrophy in elite male and female athletes: the
British experience. Eur J Appl Physiol 2004;92:592–7.
168. Pelliccia A, Maron BJ, Culasso F, Spataro A, Caselli G. Athlete’s heart in women.
Echocardiographic characterization of highly trained elite female athletes. JAMA
1996;276:211–2155.
169. Rawlins J, Carre F, Kervio G, Papadakis M, Chandra N, Edwards C et al. Ethnic differ-
ences in physiological cardiac adaptation to intense physical exercise in highly
trained female athletes. Circulation 2010;121:1078–85.
170. Makan J, Sharma S, Firoozi S, Whyte G, Jackson PG, McKenna WJ. Physiological
upper limits of ventricular cavity size in highly trained adolescent athletes. Heart
2005;91:495–9.
171. Pelliccia A,Di PaoloFM, DeBlasiis E, Quattrini FM, Pisicchio C,GuerraE et al.Preva-
lence and clinical significance of aortic root dilation in highly trained competitive
athletes. Circulation 2010;122:698–706.
172. D’AndreaA,Cocchia R,Riegler L, ScarafileR, SalernoG,Gravino Ret al.Aortic root
dimensions in elite athletes. Am J Cardiol 2010;105:1629–34.
173. Zaidi A, Ghani S, Sharma R, Oxborough D, Panoulas VF, Sheikh N et al.Physiological
right ventricular adaptation in elite athletes of African and Afro-Caribbean origin.
Circulation 2013;127:1783–92.
174. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budai A et al. 2013
ESC guidelines on the management of stable coronary artery disease. Eur Heart J
2013;34:2949–3003.
175. Sicari R, Galderisi M, Voigt JU, Habib G, Zamorano JL, Lancellotti P et al. The use of
pocket size imaging devices: a position statement of the European association of
Echocardiography. Eur J Echocardiogr 2011;12:85–7.
Multi-modality imaging and athlete’s heart Page 21 of 21
by guest on February 15, 2015
D
ow
nloaded from
 
